var title_f26_21_26960="Post-fracture pediatric hip avascular necrosis";
var content_f26_21_26960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AVN of the hip after hip fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ten year old girl with Delbet type III fracture, who required open reduction and screw fixation, developed signs of AVN nine months after injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Klane White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26960=[""].join("\n");
var outline_f26_21_26960=null;
var title_f26_21_26961="Penicillium marneffei in an AIDS patient";
var content_f26_21_26961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penicillium marneffei in an AIDS patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutaneous lesions resulted from the dissemination of the fungus from the lungs. The patient's underlying disease is AIDS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of www.doctorfungus.org. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26961=[""].join("\n");
var outline_f26_21_26961=null;
var title_f26_21_26962="Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)";
var content_f26_21_26962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86834\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?4/20/4428\">",
"         Commonly used disease modifying antirheumatic drugs (DMARDs)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/42/22178\">",
"         Patient information: Lupus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/52/835\">",
"         Patient information: Psoriatic arthritis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/40/27266\">",
"         Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/36/36419\">",
"         Patient information: Psoriatic arthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/44/24264\">",
"         Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/35/29238\">",
"         Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H260398935\">",
"      <span class=\"h1\">",
"       What are disease modifying antirheumatic drugs (DMARDs)?",
"      </span>",
"      &nbsp;&mdash;&nbsp;DMARDs are medicines that partly turn off the body&rsquo;s infection-fighting system, called the &ldquo;immune system.&rdquo; Doctors prescribe DMARDs for some diseases that happen when the immune system mistakenly attacks the body&rsquo;s own healthy tissues. These are called &ldquo;autoimmune&rdquo; diseases. Examples include rheumatoid arthritis, psoriatic arthritis, and lupus.",
"     </p>",
"     <p>",
"      DMARDs take weeks or months to work. People treated with DMARDs often take other medicines, too, until the DMARDs take effect.",
"     </p>",
"     <p>",
"      There are 2 main types of DMARDs: standard and biologic. These are described in more detail below. Some examples of common DMARDs are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef86815 \" href=\"UTD.htm?4/20/4428\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260398920\">",
"      <span class=\"h1\">",
"       Standard DMARDs",
"      </span>",
"      &nbsp;&mdash;&nbsp;This is the most common type and is what doctors usually prescribe first. These DMARDs can be taken as pills, liquids, or as an injection (shot). One common DMARD,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"       methotrexate",
"      </a>",
"      , is usually taken 1 time per week. If your doctor prescribes this medicine, make sure you take the right amount. Some people have taken too much by mistake because they took it every day instead of 1 time a week. Do not drink alcohol if you take methotrexate.",
"     </p>",
"     <p>",
"      Your doctor might prescribe more than 1 DMARD if you do not get better while taking just 1 medicine. Sometimes, people need to try different DMARDs to find 1 that works best for them. DMARDs can cause serious side effects. You will need to see your doctor on a regular basis to check for possible problems caused by DMARDs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260398905\">",
"      <span class=\"h1\">",
"       Biologic DMARDs",
"      </span>",
"      &nbsp;&mdash;&nbsp;These medicines are taken by an injection (shot) or through a small tube in a vein, called an &ldquo;IV.&rdquo; The IV medicines are given in a doctor&rsquo;s office or clinic over a period of a half-hour or longer.",
"     </p>",
"     <p>",
"      Usually, doctors prescribe biologic DMARDs only if you do not get better while taking standard DMARDs, or if you have bad side effects while taking other DMARDS. People usually take biologic medicines along with another DMARD, such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?41/59/42934?source=see_link\">",
"       methotrexate",
"      </a>",
"      .",
"     </p>",
"     <p>",
"      Some people should not take biologic DMARDS. This includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        People with serious infections",
"       </li>",
"       <li>",
"        People who have a type of cancer called lymphoma",
"       </li>",
"       <li>",
"        People who have been treated for lymphoma in the past",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260398888\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many DMARDs are not safe to take during pregnancy or if you are nursing a baby. Talk with your doctor if you could become pregnant.",
"     </p>",
"     <p>",
"      For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods.&nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260398872\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=see_link\">",
"       Patient information: Lupus (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/835?source=see_link\">",
"       Patient information: Psoriatic arthritis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=see_link\">",
"       Patient information: Psoriatic arthritis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"       Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/21/26962?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86834 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26962=[""].join("\n");
var outline_f26_21_26962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260398935\">",
"      What are disease modifying antirheumatic drugs (DMARDs)?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260398920\">",
"      Standard DMARDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260398905\">",
"      Biologic DMARDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260398888\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260398872\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/20/4428\">",
"      Commonly used disease modifying antirheumatic drugs (DMARDs)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/36/36419?source=related_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/52/835?source=related_link\">",
"      Patient information: Psoriatic arthritis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_21_26963="Sodium citrate: Pediatric drug information";
var content_f26_21_26963=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium citrate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14547?source=see_link\">",
"    see \"Sodium citrate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/6/1124?source=see_link\">",
"    see \"Sodium citrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-2;",
"     </li>",
"     <li>",
"      Oracit&reg;;",
"     </li>",
"     <li>",
"      Shohl's Solution (Modified)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Dicitrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1036079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alkalinizing Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12862158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     1 mL of oral solution contains 1 mEq of bicarbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Systemic alkalinization: 2-3 mEq bicarbonate/kg/day (2-3 mL/kg/day) in 3-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1036102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14547?source=see_link\">",
"      see \"Sodium citrate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     1 mL of oral solution contains 1 mEq of bicarbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Systemic alkalinization:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer's recommendation: Children &ge;2 years: 5-15 mL (5-15 mEq bicarbonate) per dose after meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternative recommendation: Dosing per mEq of bicarbonate: Infants and Children: 2&ndash;3 mEq bicarbonate/kg/",
"     <b>",
"      day",
"     </b>",
"     (2-3 mL/kg/",
"     <b>",
"      day",
"     </b>",
"     ) in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 10-30 mL (10-30 mEq bicarbonate) per dose after meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"     <b>",
"      Note:",
"     </b>",
"     Contains sodium 1 mEq/mL and is equivalent to bicarbonate 1 mEq/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Sodium citrate 500 mg and citric acid 334 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytra-2: Sodium citrate 500 mg and citric acid 334 mg per 5 mL (480 mL) [alcohol free, dye free, sugar free; contains propylene glycol and sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oracit&reg;: Sodium citrate 490 mg and citric acid 640 mg per 5 mL (15 mL, 30 mL, 500 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Shohl's Solution (Modified): Sodium citrate 500 mg and citric acid 300 mg per 5 mL (480 mL) [contains alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1036107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dilute with 30-90 mL of water and administer after meals to avoid saline laxative effect; chilling solution prior to dosing helps to enhance palatability. Shake well before use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1036097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect from excessive heat.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1036080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As long-term therapy to alkalinize the urine for control and/or dissolution of uric acid and cystine calculi of the urinary tract (FDA approved in children and adults); treatment of chronic metabolic acidosis secondary to chronic renal insufficiency or syndrome of renal tubular acidosis when use of potassium salt is contraindicated or undesirable (FDA approved in children and adults); buffer and neutralize gastric hydrochloric acid (FDA approved in adults).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bicitra may be confused with Polycitra",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Generally well tolerated with normal renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Tetany",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic alkalosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1036084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium citrate, citric acid, or any component; severe renal insufficiency, oliguria, or azotemia; untreated Addison's disease, adynamia episodica hereditaria (hyperkalemic periodic paralysis), acute dehydration, heat cramp, anuria, severe myocardial damage, hyperkalemia, sodium-restricted diet",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F12861344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with impaired renal function to prevent hypernatremia or alkalosis in the presence of hypocalcemia. Use caution in patients with cardiac disease, sodium- or fluid-retaining conditions (eg, cardiac failure, hypertension, peripheral/pulmonary edema, toxemia of pregnancy); conversion of citrate to bicarbonate may be impaired in patients with hepatic failure, in shock, or who are severely ill. Avoid concurrent use of aluminum-based antacids; dilute with water prior to administration to prevent saline laxative effect.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1036085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some oral solutions contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; the \"gasping syndrome\" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use oral solution containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Some  oral solutions contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; use oral solutions containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not established (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution with toxemia of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12861351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic serum (sodium, potassium, calcium, bicarbonate)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12861349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     After absorption, citrate component metabolized via oxidation to bicarbonate which produces alkalinizing effect",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1036099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &ge;95% via hepatic oxidation to bicarbonate; may be impaired in patients with hepatic failure, shock, or severe illness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (&lt;5% as sodium citrate)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1036111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/6/1124?source=see_link\">",
"      see \"Sodium citrate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well before use, take after meals, dilute each dose with 1-3 oz of water and follow with additional water; palatability is improved by chilling solution. Notify your physician if you feel weak, lightheaded, or dizzy; feel like passing out; or have numbness or tingling.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16774 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26963=[""].join("\n");
var outline_f26_21_26963=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221727\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221728\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036079\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12862158\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036102\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221713\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221700\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036107\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036097\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036080\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914136\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221746\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036084\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12861344\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036085\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300056\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221708\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221710\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221720\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12861351\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12861349\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036099\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1036111\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14547?source=related_link\">",
"      Sodium citrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/6/1124?source=related_link\">",
"      Sodium citrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_21_26964="Narrow band imaging Endosc II";
var content_f26_21_26964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Narrow band imaging in early esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A detailed view of an early cancer area in a Barrett's esophagus imaged with high resolution endoscopy and magnification (left) and with narrow band imaging with magnification (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.Barrett.nl. Copyright &copy; Amsterdam Esophageal Research Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26964=[""].join("\n");
var outline_f26_21_26964=null;
var title_f26_21_26965="Oxycodone and acetaminophen: Patient drug information";
var content_f26_21_26965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxycodone and acetaminophen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/51/9016?source=see_link\">",
"     see \"Oxycodone and acetaminophen: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/7/3191?source=see_link\">",
"     see \"Oxycodone and acetaminophen: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Endocet&reg;;",
"     </li>",
"     <li>",
"      Magnacet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;;",
"     </li>",
"     <li>",
"      Primlev&trade;;",
"     </li>",
"     <li>",
"      Roxicet&trade;;",
"     </li>",
"     <li>",
"      Roxicet&trade; 5/500;",
"     </li>",
"     <li>",
"      Tylox&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Endocet&reg;;",
"     </li>",
"     <li>",
"      Novo-Oxycodone Acet;",
"     </li>",
"     <li>",
"      Oxycocet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;;",
"     </li>",
"     <li>",
"      Percocet&reg;-Demi;",
"     </li>",
"     <li>",
"      PMS-Oxycodone-Acetaminophen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13153869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3491790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acetaminophen may cause very bad liver problems. Your risk is higher if you take more than 4 grams of acetaminophen a day, drink beer, wine, or mixed drinks, or have liver disease. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxycodone, acetaminophen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are addicted to drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705442",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid (solution):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10940 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26965=[""].join("\n");
var outline_f26_21_26965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204980\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204981\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13153869\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027938\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027937\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027942\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027943\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027945\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027940\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027941\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027946\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027947\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/51/9016?source=related_link\">",
"      Oxycodone and acetaminophen: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/7/3191?source=related_link\">",
"      Oxycodone and acetaminophen: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_21_26966="Chronic traumatic disruption of the left hemidiaphragm";
var content_f26_21_26966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87312&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Chronic traumatic disruption of the left hemidiaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CT scan&nbsp;shows a&nbsp;chronic diphragmatic hernia due to trauma. The axial view (A) using lung windows&nbsp;shows&nbsp;a portion of the colon (white arrowhead) at the apex of the hernia sac at the level of the aortic arch (black arrow). The reconstructed coronal view (B) shows the defect in the diaphragm (between the two white arrows).",
"    <div class=\"footnotes\">",
"     CT: computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26966=[""].join("\n");
var outline_f26_21_26966=null;
var title_f26_21_26967="Overview of rickets in children";
var content_f26_21_26967=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of rickets in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26967/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26967/contributors\">",
"     Thomas Carpenter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26967/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26967/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26967/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26967/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/21/26967/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal bone growth and mineralization require adequate calcium and phosphate, the two major constituents of the crystalline component of bone. Deficient mineralization can result in rickets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    osteomalacia. Rickets refers to deficient mineralization at the growth plate, as well as architectural disruption of this structure. Osteomalacia refers to impaired mineralization of the bone matrix. Rickets and osteomalacia usually occur together as long as the growth plates are open; only osteomalacia occurs after the growth plates have fused [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link\">",
"     \"Epidemiology and etiology of osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mineralization defects are classified according to the predominant mineral deficiency. Calcipenic rickets is caused by calcium deficiency, which usually is due to insufficient intake or metabolism of vitamin D, and in some cases insufficient intake or absorption of calcium in the setting of normal vitamin D levels. Phosphopenic rickets usually is caused by renal phosphate wasting. Calcipenic rickets is often but not always associated with low serum calcium levels, while phosphopenic rickets is characterized by low serum levels of phosphorus.",
"   </p>",
"   <p>",
"    An overview of the pathogenesis, clinical presentation, and the differential diagnosis of rickets is presented here. The etiology and treatment of calcipenic and phosphopenic rickets are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth plate thickness is determined by two opposing processes: chondrocyte proliferation and hypertrophy on the one hand, and vascular invasion of the growth plate followed by conversion into primary bone spongiosa on the other [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/1\">",
"     1",
"    </a>",
"    ]. Vascular invasion requires mineralization of the growth plate cartilage and is delayed or prevented by deficiency of calcium or phosphorus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In these circumstances, growth plate cartilage accumulates and the growth plate thickens. In addition, the chondrocytes of the growth plate become disorganized, losing their columnar orientation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/4-6\">",
"     4-6",
"    </a>",
"    ] with characteristic expansion of the hypertrophic zone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/7\">",
"     7",
"    </a>",
"    ]. In the bone tissue below the growth plate (metaphysis), the mineralization defect leads to the accumulation of osteoid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These abnormalities alter the overall geometry of the involved skeletal sites, leading to secondary increases in the diameters of the growth plate and metaphysis. These changes may be regarded as an attempt to compensate for decreased bone strength by increased bone size. Nonetheless, bone stability is compromised and, if the underlying condition does not improve, bowing occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcipenic and phosphopenic rickets initially manifest at the distal forearm, knee, and costochondral junctions. They are the sites of rapid bone growth where calcium and phosphorus are required for mineralization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Skeletal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skeletal findings are similar for calcipenic and phosphopenic rickets. The typical findings of advanced rickets include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed closure of the fontanelles",
"     </li>",
"     <li>",
"      Parietal and frontal bossing",
"     </li>",
"     <li>",
"      Craniotabes (soft skull bones)",
"     </li>",
"     <li>",
"      Enlargement of the costochondral junction visible as beading along the anterolateral aspects of the chest (the \"rachitic rosary\") (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81446 \" href=\"UTD.htm?19/21/19807\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Formation of Harrison sulcus (or groove) at the lower margin of the thorax caused by the muscular pull of the diaphragmatic attachments to the lower ribs",
"     </li>",
"     <li>",
"      Widening of the wrist and bowing of the distal radius and ulna",
"     </li>",
"     <li>",
"      Progressive lateral bowing of the femur and tibia (",
"      <a class=\"graphic graphic_picture graphicRef66400 \" href=\"UTD.htm?5/8/5263\">",
"       picture 1",
"      </a>",
"      ). The lower extremities tend to be predominantly affected in the heritable forms of phosphopenic rickets.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The site and type of deformity of the extremities depend upon the age of the child and the weight-bearing patterns in the limbs. Thus, deformities of the forearms and posterior bowing of the distal tibia are more common in infants, whereas an exaggeration of the normal physiological bowing of the legs (genu varum) is a characteristic finding in the toddler who has started to walk (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53635 \" href=\"UTD.htm?12/45/13022\">",
"     image 2",
"    </a>",
"    ). In the older child, valgus deformities of the legs or a windswept deformity (valgus deformity of one leg and varus deformity of the other) may be apparent. The type of deformity depends upon the biomechanical forces acting on the lower extremities at the time when the structural weakness develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the child with bow-legs\", section on 'Rickets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the child with knock-knees\", section on 'Other causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2256742\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The changes of rickets are best visualized at the growth plate of rapidly growing bones. Thus, in the upper limbs, the distal ulna is the site that best demonstrates the early signs of impaired mineralization (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80989 \" href=\"UTD.htm?40/15/41206\">",
"     image 3",
"    </a>",
"    ); the metaphyses above and below the knees are the most useful sites in the lower extremities.",
"   </p>",
"   <p>",
"    Widening of the epiphyseal plate and loss of definition of the zone of provisional calcification at the",
"    <span class=\"nowrap\">",
"     epiphyseal/metaphyseal",
"    </span>",
"    interface are the early signs of rickets (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80989 \" href=\"UTD.htm?40/15/41206\">",
"     image 3",
"    </a>",
"    ). As the disease progresses, disorganization of the growth plate becomes more apparent with cupping, splaying, formation of cortical spurs, and stippling. The appearance of the epiphyseal bone centers may be delayed, or they may be small, osteopenic, and ill-defined [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/10\">",
"     10",
"    </a>",
"    ]. The shafts of the long bones are osteopenic, and the cortices may become thin. The trabecular pattern is reduced and becomes coarse. Deformities of the shafts of the long bones typically are present and, in severe rickets, pathological fractures and Looser&rsquo;s zones (also known as Milkman pseudofractures) may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Looser&rsquo;s zones are pseudofractures, fissures, or narrow radiolucent lines 2 to 5 mm in width with sclerotic borders, and are the characteristic radiologic finding in osteomalacia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52768 \" href=\"UTD.htm?7/43/7862\">",
"     image 4",
"    </a>",
"    ). They often are bilateral and symmetric, and lie perpendicular to the cortical margins of bones. They usually are found at the femoral neck, on the medial part of the femoral shaft, immediately under the lesser trochanter or a few centimeters beneath, or on the pubic and ischial rami. They also may occur in the ulna, scapula, clavicle, rib, and metatarsal bones. Pseudofractures also can be seen as hot spots on bone scans [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Extraskeletal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extraskeletal manifestations of rickets vary depending upon the primary mineral deficiency. Hypoplasia of the dental enamel is a typical finding of calcipenic rickets, whereas dental abscesses occur more often in heritable forms of phosphopenic rickets. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=see_link&amp;anchor=H14#H14\">",
"     \"Developmental defects of the teeth\", section on 'Enamel defects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcipenic rickets can affect the musculoskeletal system with decreased muscle tone, leading to the delayed achievement of motor milestones [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Presentation with hypocalcemic seizures is frequent in the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/14\">",
"     14",
"    </a>",
"    ]. Children with calcipenic rickets also are particularly prone to acquiring infectious diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Increased sweating is a common finding in young infants with calcipenic rickets and may be caused by bone pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum alkaline phosphatase activity usually is increased markedly over the age-specific reference range in nutritional rickets, whereas the level is elevated to a lesser extent in the common form of heritable phosphopenic rickets (X-linked hypophosphatemia). Alkaline phosphatase participates in the mineralization of bone and growth plate cartilage, and is an excellent marker of disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/17\">",
"     17",
"    </a>",
"    ]. In the heritable forms of phosphopenic rickets, the serum alkaline phosphatase activity tends to be moderately elevated (400 to 800 international units per liter",
"    <span class=\"nowrap\">",
"     [IU/L])",
"    </span>",
"    whereas in calcipenic rickets, values often reach greater levels (often up to 2000",
"    <span class=\"nowrap\">",
"     IU/L).",
"    </span>",
"   </p>",
"   <p>",
"    Other biochemical findings vary depending upon the type of rickets (",
"    <a class=\"graphic graphic_table graphicRef81032 \" href=\"UTD.htm?12/34/12845\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/18\">",
"     18",
"    </a>",
"    ]. Serum phosphorus concentrations usually are low in both calcipenic and phosphopenic rickets. The serum calcium concentration may be either decreased or normal in calcipenic rickets, depending on the stage of rickets; serum calcium usually is normal in phosphopenic rickets. The total reabsorption of phosphorus (TRP) and the maximal tubular reabsorption of phosphorus per glomerular filtration rate",
"    <span class=\"nowrap\">",
"     (TmP/GFR)",
"    </span>",
"    usually are decreased in both types of rickets, but usually are more pronounced in renal phosphate wasting types. By contrast, these values are quite elevated in the setting of nutritional phosphate deprivation.",
"   </p>",
"   <p>",
"    The serum concentration of parathyroid hormone (PTH) typically is quite elevated in calcipenic rickets. In contrast, PTH concentrations are usually normal or modestly elevated in phosphopenic rickets. Serum concentrations of 25-hydroxyvitamin D (25OHD) reflect the amount of vitamin D stored in the body and, consequently, are low in vitamin D deficiency. Serum concentrations of 1,25-dihydroxyvitamin D (1,25[OH]",
"    <sub>",
"     2",
"    </sub>",
"    D) can be low, normal, or increased in calcipenic rickets. In some forms of phosphopenic rickets (X-linked hypophosphatemic rickets [XLH], tumor-induced osteomalacia [TIO]), serum concentrations of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D may be low or inappropriately normal (in view of the ambient hypophosphatemia, which should serve to increase production of the metabolite). In other forms of phosphopenic rickets (hereditary hypophosphatemic rickets with hypercalcuria [HHRH]), the serum concentration of 1,25(OH)",
"    <sub>",
"     2",
"    </sub>",
"    D may be elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a child with clinical signs of rickets should include a dietary history with particular attention given to calcium and vitamin D intake along with a medication history, and a history of sun exposure. Radiographic evaluation of a child with rickets should include, at a minimum, plain films of the wrist and hand or knees to evaluate the epiphyseal plates. (See",
"    <a class=\"local\" href=\"#H2256742\">",
"     'Radiographic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1640853\">",
"    <span class=\"h2\">",
"     Initial classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum calcium, inorganic phosphorus, and parathyroid hormone (PTH) concentrations are used to determine the initial classification of rickets (",
"    <a class=\"graphic graphic_algorithm graphicRef79880 \" href=\"UTD.htm?37/6/37997\">",
"     algorithm 1",
"    </a>",
"    ). Rickets is an unlikely diagnosis if all of these values are normal. Serum creatinine and liver enzymes should be measured to screen for renal and liver disease, respectively. (See",
"    <a class=\"local\" href=\"#H1640164\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the serum phosphorus concentration is low but PTH is considerably elevated, then a provisional diagnosis of calcipenic rickets can be made. The diagnosis is confirmed if appropriate healing is observed on x-ray during the course of therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Calcipenic rickets'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the serum phosphorus concentration is low but PTH is normal, then phosphopenic rickets should be suspected. Demonstration of renal phosphate wasting will identify most forms of phosphopenic rickets, but in cases of inadequate supply of dietary phosphorus (albeit an uncommon event), enhanced renal conservation of phosphate will be evident. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Phosphopenic rickets'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of rickets include conditions that lead to hypocalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypophosphatemia as a result of decreased intake, malabsorption,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased excretion of calcium, phosphate, or vitamin D&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67378 \" href=\"UTD.htm?11/53/12124\">",
"     table 2",
"    </a>",
"    ). To determine the optimal treatment, the common nutritional causes of rickets must be distinguished from the forms caused by a gastrointestinal or renal disease or an inherited disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Calcipenic rickets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of acquired rickets are calcipenic. If the serum phosphorus concentration is low but PTH is considerably elevated, then a provisional diagnosis of calcipenic rickets can be made. Elevated PTH levels are occasionally observed at diagnosis in X-linked hypophosphatemia (XLH), the most frequently encountered form of phosphopenic rickets. Therefore, if calcipenic rickets is provisionally diagnosed, it is important to observe appropriate healing during the course of therapy and, in the event of treatment failure, an alternate diagnosis should be considered.",
"   </p>",
"   <p>",
"    Calcipenic rickets can be further divided into the following disorders, which can be distinguished by measuring serum levels of 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25[OH]",
"    <sub>",
"     2",
"    </sub>",
"    D) (",
"    <a class=\"graphic graphic_algorithm graphicRef80602 \" href=\"UTD.htm?10/28/10702\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81032 \" href=\"UTD.htm?12/34/12845\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nutritional rickets &ndash; Calcipenic rickets is usually caused by dietary deficiency of vitamin D. Occasionally, nutritional rickets is caused by deficiency of dietary calcium or a mixed deficiency of vitamin D and calcium. 25OHD levels are typically low, but they may be normal if there is associated calcium deficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vitamin D-dependent rickets type I &ndash; Vitamin D-dependent rickets type I (VDDR-I), is also known as pseudovitamin D deficiency because its clinical manifestations mimic those of vitamin D deficiency. This is a rare disorder caused by a defect in the vitamin D 1-alpha hydroxylase enzyme that converts 25OHD into the active metabolite 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D. Serum levels of 25OHD are normal and 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D levels are low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hereditary vitamin D-resistant rickets &ndash; Hereditary vitamin D-resistant rickets (HVDRR), also known as vitamin D-dependent rickets type II, is a rare form of calcipenic rickets caused by a mutation in the gene that encodes the vitamin D receptor, leading to vitamin D resistance. 25OHD levels are normal and 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D levels are high or very high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Secondary defects in vitamin D metabolism or absorption of calcium or vitamin D &ndash; This can occur in extremely severe liver disease or in intestinal disorders such as celiac disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and management of each of these disorders are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Phosphopenic rickets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphopenic rickets is characterized by low serum phosphorus with normal PTH concentrations. Phosphopenic rickets in children and adolescents is almost always caused by renal phosphate wasting, which may be isolated or part of a generalized renal tubular disorder. When phosphopenic rickets is suspected, it is important to establish whether renal phosphate wasting is present. This is done by performing a fasting urine collection (usually for two hours) and obtaining a blood sample during the course of the urine collection for determination of the total reabsorption of phosphorus (TRP) and maximal tubular reabsorption of phosphorus per glomerular filtration rate",
"    <span class=\"nowrap\">",
"     (TmP/GFR).",
"    </span>",
"    The finding of very low",
"    <span class=\"nowrap\">",
"     TmP/GFR",
"    </span>",
"    confirms renal phosphate wasting. In contrast, very high TRP and",
"    <span class=\"nowrap\">",
"     TmP/GFR",
"    </span>",
"    indicate renal conservation of phosphate, implicating compromised dietary supply or intestinal absorption.",
"   </p>",
"   <p>",
"    The different causes of phosphate wasting can be distinguished by measuring urinary amino acids, bicarbonate, glucose, and calcium concentrations (",
"    <a class=\"graphic graphic_algorithm graphicRef59221 \" href=\"UTD.htm?28/51/29502\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81032 \" href=\"UTD.htm?12/34/12845\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal tubular disorders &ndash; Renal tubular disorders such as Fanconi syndrome can cause rickets due to renal loss of phosphate. Fanconi syndrome is characterized by hypophosphatemia due to phosphaturia, renal glucosuria (glucosuria with a normal plasma glucose concentration), aminoaciduria, tubular proteinuria, and proximal renal tubular acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=see_link&amp;anchor=H12#H12\">",
"       \"Etiology and clinical manifestations of renal tubular acidosis in infants and children\", section on 'Fanconi syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      X-linked hypophosphatemic rickets &ndash; X-linked hypophosphatemic rickets (XLH) is the most common cause of isolated renal phosphate loss. It is a heritable disorder, caused by mutations in the",
"      <strong>",
"       Ph",
"      </strong>",
"      osphate regulating",
"      <strong>",
"       E",
"      </strong>",
"      ndopeptidase on the",
"      <strong>",
"       X",
"      </strong>",
"      chromosome (PHEX) gene. Renal phosphate wasting is present from birth, but the disorder tends to become clinically apparent when the child begins to walk, causing bowing of the legs. A less common autosomal dominant form of hypophosphatemic rickets also exists. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H2#H2\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'X-linked'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H10#H10\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Autosomal dominant'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tumor-induced osteomalacia &ndash; Tumor-induced osteomalacia (TIO) also causes isolated phosphate loss. It is an acquired disorder associated with a tumor, which usually is benign. These tumors express a variety of factors, one of which, FGF23, acts at the kidney to induce renal phosphate wasting. Complete removal of the tumor will remove the source of FGF23, thereby curing the disorder. TIO tends to present in late childhood or adolescence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H22#H22\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Tumor-induced osteomalacia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hereditary hypophosphatemic rickets with hypercalciuria &ndash; Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is an autosomal recessive disease, and is another rare cause of phosphopenic rickets. This disorder is distinguished from the other forms of hypophosphatemic rickets by an elevated serum 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D concentration and increased urinary calcium excretion. Because the treatment for this disorder is distinct, it is important to evaluate for HHRH in every patient with phosphopenic rickets before initiating therapy, by measuring serum 1,25(OH)",
"      <sub>",
"       2",
"      </sub>",
"      D and urinary calcium excretion. The disorder is due to loss of function mutations in Na-Pi IIc, a sodium-phosphate transporter expressed in renal tubules. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H16#H16\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Hypophosphatemic rickets with hypercalciuria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1640164\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal insufficiency &ndash; Renal dysfunction is an important cause of bone disease (renal osteodystrophy), which can include rickets. In children with suspected rickets, renal function should be evaluated by measuring serum creatinine. Bone disease occurs in children with renal insufficiency for many reasons, including reduced formation of 1,25-dihydroxyvitamin D (1,25[OH]",
"      <sub>",
"       2",
"      </sub>",
"      D), metabolic acidosis, administration of aluminum, and secondary hyperparathyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=see_link\">",
"       \"Bone metabolism and renal osteodystrophy in children with chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skeletal dysplasia &ndash; Skeletal dysplasia (eg, achondroplasia, pseudoachondroplasia, metaphyseal chondrodysplasia) is another cause of bilateral, symmetric bowed legs. The radiographic features can be similar to those of rickets. However, serum inorganic phosphorus and parathyroid hormone (PTH) concentrations usually are normal in children with skeletal dysplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the child with bow-legs\", section on 'Skeletal dysplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liver disease &ndash; Elevations of serum alkaline phosphatase activity is seen in rickets, but also can be caused by liver disease. The possibility of liver disease can be evaluated by measuring liver enzymes (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], and gamma-glutamyl transpeptidase [GGT]). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transient hyperphosphatasemia &ndash; Children with isolated elevations of serum alkaline phosphatase but normal liver enzymes, and no radiographic evidence of rickets, may have transient hyperphosphatasemia of infancy and early childhood. This is usually a benign condition that follows a minor infectious illness that spontaneously remits over a several-month period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43989?source=see_link\">",
"       \"Transient hyperphosphatasemia of infancy and early childhood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary hypoparathyroidism &ndash; Primary hypoparathyroidism causes marked hypocalcemia, but is usually not associated with rickets. This observation suggests that low serum phosphorus",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PTH itself may play roles in mediating the growth plate lesion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=see_link&amp;anchor=H7#H7\">",
"       \"Etiology of hypocalcemia in infants and children\", section on 'Hypoparathyroidism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypophosphatasia &ndash; Hypophosphatasia is a rare genetic disorder of alkaline phosphatase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26967/abstract/19\">",
"       19",
"      </a>",
"      ]. Like rickets, it is characterized by bone demineralization. In contrast to rickets, serum alkaline phosphatase activity is very low. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=see_link&amp;anchor=H17#H17\">",
"       \"Epidemiology and etiology of osteomalacia\", section on 'Hypophosphatasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blount disease &ndash; Blount disease is a pathologic varus deformity of the knee that results from disruption of normal cartilage growth at the medial aspect of the proximal tibial physis. It can be distinguished from rickets by distinct radiographic findings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to the child with bow-legs\", section on 'Blount disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2256073\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rickets refers to the changes at the growth plate caused by deficient mineralization of bone and occurs before the closure of the growth plates. Osteomalacia refers to impaired mineralization of bone and usually occurs together with rickets. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rickets is classified according to the predominant mineral deficiency. Calcipenic rickets is caused by calcium deficiency, which usually is due to insufficient intake of or metabolism of vitamin D, and in some cases insufficient intake or absorption of calcium in the setting of normal vitamin D levels. Phosphopenic rickets usually is caused by renal phosphate wasting. Serum calcium levels are often, but not always, decreased in calcipenic rickets. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Calcipenic rickets usually is caused by dietary deficiency of vitamin D",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcium; this is the most common cause of rickets worldwide. Rarely, it is caused by genetic defects in vitamin D metabolism or action leading to vitamin D resistance. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Calcipenic rickets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Phosphopenic rickets in children and adolescents is almost always caused by renal phosphate wasting, which is usually an isolated phenomenon, but may be part of a generalized tubular disorder such as Fanconi syndrome, or may rarely result from inadequate dietary phosphorus or intestinal malabsorption. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Phosphopenic rickets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The skeletal findings are similar for calcipenic and phosphopenic rickets, and may include delayed closure of the fontanelles, parietal and frontal bossing, enlargement of the costochondral junction (&ldquo;rachitic rosary&rdquo;), widening of the wrist, and lateral bowing of the femur and tibia (bow legs) (",
"      <a class=\"graphic graphic_picture graphicRef66400 \" href=\"UTD.htm?5/8/5263\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Skeletal findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic findings of rickets include widening of the epiphyseal plate and loss of definition of the zone of provisional calcification at the",
"      <span class=\"nowrap\">",
"       epiphyseal/metaphyseal",
"      </span>",
"      interface, progressing to disorganization of the growth plate with cupping, splaying, and formation of cortical spurs (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80989 \" href=\"UTD.htm?40/15/41206\">",
"       image 3",
"      </a>",
"      ). The changes are best seen in the distal ulna and the metaphyses above and below the knee. (See",
"      <a class=\"local\" href=\"#H2256742\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The concentration of serum alkaline phosphatase is elevated in both types of rickets, and it is a good marker of disease activity. Other biochemical findings include hypocalcemia and hypophosphatemia, but the pattern varies depending on the type and severity of the rickets (",
"      <a class=\"graphic graphic_table graphicRef81032 \" href=\"UTD.htm?12/34/12845\">",
"       table 1",
"      </a>",
"      ). Serum concentration of parathyroid hormone (PTH) typically is elevated in calcipenic rickets, but not in phosphopenic rickets. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach to suspected rickets is to use measurements of serum inorganic phosphorus and PTH to distinguish calcipenic from phosphopenic rickets (",
"      <a class=\"graphic graphic_algorithm graphicRef79880 \" href=\"UTD.htm?37/6/37997\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1640853\">",
"       'Initial classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children with calcipenic rickets, measurements of serum 25-hydroxyvitamin D (25OHD) help to distinguish rickets caused by vitamin D deficiency (the most common form) from other causes of calcipenic rickets (",
"      <a class=\"graphic graphic_algorithm graphicRef80602 \" href=\"UTD.htm?10/28/10702\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Calcipenic rickets'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link\">",
"       \"Etiology and treatment of calcipenic rickets in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children with phosphopenic rickets, the degree of renal excretion of phosphate should be documented. Causes of renal phosphate wasting can be further distinguished by measuring serum 1,25-dihydroxyvitamin D and urinary excretion of amino acids, bicarbonate, glucose, and calcium (",
"      <a class=\"graphic graphic_algorithm graphicRef59221 \" href=\"UTD.htm?28/51/29502\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Phosphopenic rickets'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/1\">",
"      Pitt MJ. Rickets and osteomalacia are still around. Radiol Clin North Am 1991; 29:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/2\">",
"      Shapiro IM, Boyde A. Mineralization of normal and rachitic chick growth cartilage: vascular canals, cartilage calcification and osteogenesis. Scanning Microsc 1987; 1:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/3\">",
"      Hunter WL, Arsenault AL, Hodsman AB. Rearrangement of the metaphyseal vasculature of the rat growth plate in rickets and rachitic reversal: a model of vascular arrest and angiogenesis renewed. Anat Rec 1991; 229:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/4\">",
"      Lacey DL, Huffer WE. Studies on the pathogenesis of avian rickets. I. Changes in epiphyseal and metaphyseal vessels in hypocalcemic and hypophosphatemic rickets. Am J Pathol 1982; 109:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/5\">",
"      Huffer WE, Lacey DL. Studies on the pathogenesis of avian rickets II. Necrosis of perforating epiphyseal vessels during recovery from rickets in chicks caused by vitamin D3 deficiency. Am J Pathol 1982; 109:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/6\">",
"      Takechi M, Itakura C. Ultrastructural studies of the epiphyseal plate of chicks fed a vitamin D-deficient and low-calcium diet. J Comp Pathol 1995; 113:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/7\">",
"      Sabbagh Y, Carpenter TO, Demay MB. Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci U S A 2005; 102:9637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/8\">",
"      Rauch F. The rachitic bone. Endocr Dev 2003; 6:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/9\">",
"      Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/10\">",
"      Oestreich AE. The acrophysis: a unifying concept for understanding enchondral bone growth and its disorders. II. Abnormal growth. Skeletal Radiol 2004; 33:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/11\">",
"      Chapman T, Sugar N, Done S, et al. Fractures in infants and toddlers with rickets. Pediatr Radiol 2010; 40:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/12\">",
"      Kim S, Park CH, Chung YS. Hypophosphatemic osteomalacia demonstrated by Tc-99m MDP bone scan: a case report. Clin Nucl Med 2000; 25:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/13\">",
"      Carvalho NF, Kenney RD, Carrington PH, Hall DE. Severe nutritional deficiencies in toddlers resulting from health food milk alternatives. Pediatrics 2001; 107:E46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/14\">",
"      Robinson PD, H&ouml;gler W, Craig ME, et al. The re-emerging burden of rickets: a decade of experience from Sydney. Arch Dis Child 2006; 91:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/15\">",
"      Muhe L, Lulseged S, Mason KE, Simoes EA. Case-control study of the role of nutritional rickets in the risk of developing pneumonia in Ethiopian children. Lancet 1997; 349:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/16\">",
"      Najada AS, Habashneh MS, Khader M. The frequency of nutritional rickets among hospitalized infants and its relation to respiratory diseases. J Trop Pediatr 2004; 50:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/17\">",
"      Whyte MP. Physiological role of alkaline phosphatase explored in hypophosphatasia. Ann N Y Acad Sci 2010; 1192:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/18\">",
"      Baroncelli GI, Bertelloni S, Ceccarelli C, et al. Bone turnover in children with vitamin D deficiency rickets before and during treatment. Acta Paediatr 2000; 89:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26967/abstract/19\">",
"      Mohn A, De Leonibus C, de Giorgis T, et al. Hypophosphatasia in a child with widened anterior fontanelle: lessons learned from late diagnosis and incorrect treatment. Acta Paediatr 2011; 100:e43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5856 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26967=[""].join("\n");
var outline_f26_21_26967=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2256073\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Skeletal findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2256742\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Extraskeletal findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1640853\">",
"      Initial classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Calcipenic rickets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Phosphopenic rickets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1640164\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2256073\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5856|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?37/6/37997\" title=\"algorithm 1\">",
"      Diagnostic approach in suspected rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/28/10702\" title=\"algorithm 2\">",
"      Approach to calcipenic rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/51/29502\" title=\"algorithm 3\">",
"      Diagnostic approach to phosphopenic rickets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5856|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/21/19807\" title=\"diagnostic image 1\">",
"      Rachitic Rosary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/45/13022\" title=\"diagnostic image 2\">",
"      Vit D deficiency rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/15/41206\" title=\"diagnostic image 3\">",
"      Rickets wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/43/7862\" title=\"diagnostic image 4\">",
"      Pseudofractures in osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5856|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/8/5263\" title=\"picture 1\">",
"      Rickets bow-legs 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5856|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/34/12845\" title=\"table 1\">",
"      Biochemical findings rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/53/12124\" title=\"table 2\">",
"      Etiology of rickets",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=related_link\">",
"      Approach to the child with bow-legs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=related_link\">",
"      Approach to the child with knock-knees",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28042?source=related_link\">",
"      Bone metabolism and renal osteodystrophy in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27494?source=related_link\">",
"      Epidemiology and etiology of osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17768?source=related_link\">",
"      Etiology and clinical manifestations of renal tubular acidosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43989?source=related_link\">",
"      Transient hyperphosphatasemia of infancy and early childhood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_21_26968="Heart failure and left ventricular dysfunction in rheumatoid arthritis";
var content_f26_21_26968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heart failure and left ventricular dysfunction in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26968/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26968/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26968/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26968/contributors\">",
"     Katherine P Liao, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26968/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26968/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/21/26968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a common clinical syndrome that can result from a variety of structural or functional cardiac disorders. There is an increased incidence of HF in patients with rheumatoid arthritis (RA) compared with the general population, and HF may contribute to the shortened life expectancy observed in RA. In addition to symptomatic HF, asymptomatic left ventricular (LV) systolic dysfunction, defined by a reduced LV ejection fraction, is also more prevalent among patients with RA. Attempts to eliminate the risk of HF in patients with RA may significantly improve their survival.",
"   </p>",
"   <p>",
"    Issues related to HF in patients with RA will be reviewed here. Other cardiac manifestations of RA and the issue of HF as a complication of targeted therapy directed against tumor necrosis factor-alpha are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\", section on 'Cardiac disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Population-based studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are growing numbers of population-based estimates of the incidence, prevalence, and prognosis of HF in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/1\">",
"     1",
"    </a>",
"    ]. Data suggest that the incidence of HF in patients with RA is increased compared with a population of similar age and sex distribution without RA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study involved 575 patients with RA and 583 patients without RA [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]; the incidence of HF was significantly higher among patients with RA after adjustment for age, sex, known cardiovascular risk factors, and the presence of ischemic heart disease (1.99 versus 1.16 cases per 100 person-years, respectively).",
"     </li>",
"     <li>",
"      In a second series, 603 patients with RA were compared with 603 controls without RA [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/3\">",
"       3",
"      </a>",
"      ]. The cumulative incidence of HF but not ischemic heart disease was significantly higher in those with RA (37 versus 28 percent, at 30 years of follow-up).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     LV systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data exist concerning the prevalence of LV systolic dysfunction in patients with RA. In a cross-sectional study that compared 226 patients with RA with 3960 members of the general population, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LV systolic dysfunction, defined as an LV ejection fraction (LVEF) &lt;40 percent on echocardiography, was significantly more common in patients with RA (5.3 versus 1.8 percent).",
"     </li>",
"     <li>",
"      Even after adjustment for hypertension, diabetes, and exposure to cigarette smoke, all of which were greater among the RA patients, LV systolic dysfunction was still 3.2 times more common in the RA group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies typically use Doppler echocardiography to assess diastolic heart function. The measurements usually consist of transmitral blood flow velocity in early (E) and late (A) diastole, the ratio of these velocities",
"    <span class=\"nowrap\">",
"     (E/A",
"    </span>",
"    ratio), and valve annulus velocities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, 35 RA patients and 30 healthy subjects were examined with Doppler echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/7\">",
"     7",
"    </a>",
"    ]. Impaired right ventricular filling, an index of RV diastolic function, was noted in 34 percent of the RA patients but in only 7 percent of the controls.",
"   </p>",
"   <p>",
"    These echocardiographic measures are more frequently abnormal in patients with RA than in healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. As an example, a significantly higher prevalence of impaired LV diastolic relaxation was found in a group of 47 patients with RA of at least five years' duration compared with healthy age- and sex-matched controls (66 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in the general population, the prevalence of diastolic dysfunction increases with age. However, some studies suggest that RA disease duration is a risk factor that is independent of patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Left ventricular hypertrophy (LVH) is a recognized cause of diastolic HF, but it is unclear whether left ventricular (LV) mass is higher or lower in RA patients compared with controls. In a study of 89 RA patients without clinical cardiovascular disease and 89 healthy matched controls who were examined echocardiographically, the prevalence of LVH was significantly greater in those with RA than in controls (18 versus 6.7 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a study of 75 RA patients and 225 matched controls, also without clinical cardiovascular disease, found that LV mass was lower in RA patients than in controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/13\">",
"     13",
"    </a>",
"    ]. The mean LV mass, measured using cardiac MRI, for RA patients was 26 g or 18 percent lower than in controls. End diastolic volumes did not significantly differ between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mortality due to heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA is associated with an increased mortality rate compared with the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=see_link&amp;anchor=H12#H12\">",
"     \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies indicate that deaths are attributed to HF more often for patients with RA than for the general population. This difference appears to be the result of an increased incidence of HF in RA rather than a worse prognosis once HF develops [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased mortality due to HF in patients with RA was noted in a study that compared 1000 patients with RA to matched controls; the cause of death was determined from the death certificate [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/14\">",
"       14",
"      </a>",
"      ]. There was a 60 percent increased rate of death attributed to HF in patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/14\">",
"       14",
"      </a>",
"      ]. Nonsteroidal drug (NSAID) use, which itself is associated with cardiovascular risk, was not specifically reported or analyzed in this study. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antirheumatic drug therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The prognosis of patients with RA and clinically apparent HF is not significantly worse than that of patients with HF in general. In a Mayo Clinic study cited above [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/3\">",
"       3",
"      </a>",
"      ], the mortality due to HF in patients with RA and HF was not significantly different from that of population controls of the same age and sex with HF (hazard ratios of 4.86 versus 4.25).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiopathogenic mechanisms responsible for an increased risk of HF in RA may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammatory mediators",
"     </li>",
"     <li>",
"      Antirheumatic drug therapy",
"     </li>",
"     <li>",
"      Amyloidosis",
"     </li>",
"     <li>",
"      Ischemic heart disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory stimuli may be involved in the initiation of HF in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/15\">",
"     15",
"    </a>",
"    ]. In a longitudinal cohort of patients with RA who developed HF, the proportion with an erythrocyte sedimentation (ESR) &gt;39",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    was highest during the six-month period immediately preceding the new-onset HF, as compared with the average ESR during the entire remaining follow-up period (23 versus 11 percent). The proportion of patients with anemia also peaked during the six-month period after HF, consistent with an effect of inflammation.",
"   </p>",
"   <p>",
"    Tumor necrosis factor-alpha (TNF) is one of the major proinflammatory cytokines involved in the pathogenesis of RA. Randomized trials with anti-TNF alpha therapies in non-RA patients failed to show an improvement in clinical HF or morbidity and mortality. Data from one trial also suggested that high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , a chimeric monoclonal antibody inhibitor of TNF, actually worsens existing HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a cohort of Veterans Administration patients with RA and without RA compared with a similar group who had received anti-TNF therapy showed no difference among the groups in either HF exacerbation or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antirheumatic drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications used in the treatment of RA may contribute to HF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TNF inhibitors &mdash; The potential association of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      with cardiac dysfunction is presented in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAIDs &mdash; Nonselective NSAID use is not associated with a first occurrence of heart failure (HF); however, it can cause a worsening of preexisting HF. The major mechanism for HF exacerbation is an increase in afterload resulting from NSAID-induced systemic vasoconstriction, which can lead to a further reduction in cardiac contractility and cardiac output in advanced HF. Data are more limited, but there is a similar concern with the COX-2 selective agents. Several studies have presented data indicating that the selective COX-2 inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      may have an improved cardiorenal safety profile compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      (nonselective NSAIDs) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link&amp;anchor=H7#H7\">",
"       \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H8#H8\">",
"       \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Heart failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antimalarial drugs &mdash; Antimalarial drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      can cause a drug-induced cardiomyopathy. This complication of antimalarial drugs is rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link&amp;anchor=H10#H10\">",
"       \"Drug-induced myopathies\", section on 'Antimalarial drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids &mdash; Therapeutic use of glucocorticoids has been associated with dose-dependent increased rates of heart failure, myocardial infarction, stroke, and all-cause mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. In a large observational study, the risk of heart failure appeared to increase with the daily dose of glucocorticoids prescribed, with a rate ratio of 3.72 (95% CI 2.71-5.12) with greater than or equal to 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or its equivalent compared with nonusers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/18\">",
"       18",
"      </a>",
"      ]. The cardiovascular risk was higher for those who had continuing prescriptions than for those who had intermittent prescribing of glucocorticoids, and it was higher for those using glucocorticoids during the six months prior to the cardiovascular event versus those who used glucocorticoids at an earlier time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H9#H9\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Cardiovascular disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link&amp;anchor=H10#H10\">",
"       \"Major side effects of systemic glucocorticoids\", section on 'Lipids'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some data suggest that glucocorticoids interact with rheumatoid factor status to modulate the occurrence of cardiovascular events in RA. This was illustrated in a population-based study from the Rochester Epidemiology Project that reported the following findings [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rheumatoid factor-positive patients were at increased risk of cardiovascular events, including myocardial infarction, heart failure, and death from cardiovascular causes. The risk of cardiovascular events was particularly pronounced among rheumatoid factor-positive patients with high cumulative exposure to glucocorticoids, high average daily dose, and recent use.",
"     </li>",
"     <li>",
"      Rheumatoid factor-positive patients with high cumulative exposure had a threefold increased risk (hazard ratio 3.06, 95% CI 1.81-5.18). This effect persisted after adjustments for demographic features, baseline cardiovascular risk factors, and RA characteristics.",
"     </li>",
"     <li>",
"      In contrast, rheumatoid factor-negative patients were not at increased risk of cardiovascular events, regardless of glucocorticoid exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Amyloidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary amyloidosis (AA) due to RA can cause HF due to an infiltrative cardiomyopathy. This complication of RA is now extremely rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic cardiomyopathy is the most common cause of HF due to systolic dysfunction in the general population. HF is also likely to result from an ischemic cardiomyopathy in a significant percentage of patients with RA, given that the prevalence of coronary disease is increased in patients with RA compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in a cohort of patients with RA with a significantly increased incidence of HF, the cumulative incidence of symptomatic ischemic heart disease, including angina and hospitalization for myocardial infarction, was not significantly different from that of age and sex-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/3\">",
"     3",
"    </a>",
"    ]. The 30-year incidence among patients with RA was 38 percent versus 35 percent in the control group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link\">",
"     \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NSAIDs and COX-2 inhibitors can also have adverse effects on the cardiovascular system, leading to ischemic heart disease. At least two NSAIDs can interfere with the cardioprotective effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major categories of symptoms in HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those due to excess fluid accumulation (dyspnea, edema, hepatic congestion, and ascites)",
"     </li>",
"     <li>",
"      Those caused by reductions in cardiac output (fatigue, weakness), which are most pronounced with exertion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with RA and HF may experience fewer exertional symptoms than patients with HF who do not have RA, because RA patients have impaired mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Symptomatic HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the patient with HF with or without RA uses the history, physical examination, laboratory studies, chest x-ray, electrocardiography (ECG), and echocardiogram to establish the diagnosis, determine the etiology, and assess severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are additional issues related to etiology that are relatively unique to the diagnosis of HF in patients with RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, some antirheumatic drugs may cause",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exacerbate HF. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antirheumatic drug therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amyloidosis due to an inflammatory disease (AA amyloid) can cause a symptomatic infiltrative cardiomyopathy, although the frequency is much lower than in other common forms of amyloidosis. If present, other systemic involvement due to AA amyloid usually accompanies HF, particularly renal disease. Biopsy is required for the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"       \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Asymptomatic LV dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RA may have asymptomatic LV dysfunction, which can often only be detected by echocardiography or other cardiac imaging. The frequency with which this occurs was evaluated in a study of 226 consecutive patients with RA who underwent clinical evaluation, ECG, echocardiography, and measurements of plasma levels of brain natriuretic peptide (BNP) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/6\">",
"     6",
"    </a>",
"    ]. Eight patients (3.5 percent) had asymptomatic LV dysfunction with an LVEF &le;50 percent. Most such patients had an abnormal ECG.",
"   </p>",
"   <p>",
"    Screening for asymptomatic LV dysfunction is not recommended in patients with or without RA. Thus, the diagnosis of asymptomatic LV dysfunction is usually made by echocardiography performed for another indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=see_link\">",
"     \"Screening for asymptomatic left ventricular dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes disorders in patients with RA that produce symptoms, signs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging findings similar to those observed in HF. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interstitial lung disease &mdash; Symptoms and signs of interstitial lung disease, caused by either active alveolitis or fibrosis due to previous lung inflammation, can be confused with the manifestations of HF. Rales may be audible, and the interstitial fibrosis demonstrated by chest radiography may be difficult to distinguish from interstitial edema caused by HF.",
"      <br/>",
"      <br/>",
"      In this setting, echocardiography provides important diagnostic information related to ventricular size and function. High resolution computed tomography (CT) scan of the chest is useful in assessing the lung disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"       \"Interstitial lung disease in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pericardial disease &mdash; Pericardial disease, particularly effusion without tamponade, is a common finding in RA. Both HF and a pericardial effusion without tamponade can be associated with an enlarged cardiac silhouette on chest radiography. These disorders can be distinguished by findings on echocardiography, which is the method of choice for evaluating most pericardial diseases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=see_link\">",
"       \"Echocardiographic evaluation of the pericardium\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The signs and symptoms of constrictive pericardial disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiac tamponade can be confused with HF. These disorders are also usually distinguished by findings on echocardiography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"       \"Constrictive pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention to risk factors for HF that have been identified in the general population and to some factors more specific to those with RA may reduce the risk of HF. Interventions addressing these risk factors for HF can be recommended for those with RA. Prevention of HF in the general population is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link&amp;anchor=H18#H18\">",
"     \"Epidemiology and causes of heart failure\", section on 'Prevention of heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest a higher prevalence of established risk factors for HF in patients with RA compared with the general population. These risk factors include longstanding hypertension, coronary artery disease, diabetes mellitus, cigarette smoking, obesity, and LV hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to risk factor modification, effective treatment of RA may also reduce the incidence of HF. The following observations illustrate the range of findings with different antirheumatic drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benefit from disease modifying antirheumatic drugs (DMARDs) was suggested in a retrospective case control study of 41,885 RA patients that assessed DMARD use relative to the risk of hospitalization with newly diagnosed HF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/22\">",
"       22",
"      </a>",
"      ]. After adjustment for HF risk factors, the relative risk (RR) was significantly lower for current DMARD users than for nonusers (RR 0.7, 95% CI 0.6-0.9). The use of anti-TNF therapy was also protective (RR of 0.5, 95% CI 0.2-0.9) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The correlation between anti-TNF agent use and the incidence of HF was evaluated over a two-year period among 13,171 patients with RA and 2568 patients with osteoarthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/23\">",
"       23",
"      </a>",
"      ]. The incidence of HF was significantly lower among RA patients who were receiving anti-TNF therapies (3.1 versus 3.8 percent). Although the development of HF was unrelated to anti-TNF therapy in this study, the study's design was limited by the fact that TNF treatments were not allocated on a randomized basis and by the dependence of patient reporting of HF events.",
"      <br/>",
"      <br/>",
"      A short-term study found that treatment with a TNF inhibitor (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ) of patients with active RA and without clinical evidence of HF was associated with reduced levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) after 16 weeks of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26968/abstract/24\">",
"       24",
"      </a>",
"      ]. The changes in NT-proBNP were significantly associated with changes in the pulse pressure, although the trend toward a reduction in the latter did not achieve significance. The clinical implications of such changes in patients with RA remain to be shown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If anti-TNF therapy has a beneficial cardiac effect in RA, it is most likely to be due to control of the inflammatory process. Randomized trials of such therapy in patients with HF have found either no effect or a possible effect. In addition, new-onset HF has been described in a small number of patients in the absence of major cardiovascular risk factors. The labels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    contain the following disease-related concern: \"Use with caution in patients with HF or decreased LV function; worsening and new-onset HF has been reported.\" The supportive data are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two management issues that must be addressed in RA patients with HF: avoidance of exacerbation of HF while treating RA, and specific therapy of the HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Avoiding exacerbation of HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;TNF inhibitors, nonselective NSAIDs, COX-2 selective agents, and glucocorticoids all can have adverse effects in RA patients with HF. As a result, drugs without significant cardiotoxicity are preferred as initial therapy. These include antimalarial drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with RA and mild HF (NYHA functional class I or II) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) whose arthritis is refractory to other DMARDs or biologic agents, targeted TNF inhibition might be considered. If the use of anti-TNF treatment is entertained, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiology consultation",
"     </li>",
"     <li>",
"      Baseline echocardiography",
"     </li>",
"     <li>",
"      Close follow-up",
"     </li>",
"     <li>",
"      Avoidance of high TNF inhibitor doses (eg, more than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      3",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      40 mg every two weeks, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/week)",
"      </span>",
"     </li>",
"     <li>",
"      Prompt discontinuation of anti-TNF therapy if HF worsens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest avoiding NSAIDs (except low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    being used for cardioprotection) and selective COX-2 inhibitors in patients with known LV dysfunction, whether or not they are symptomatic. Glucocorticoids should also be used in the lowest possible dose for the shortest time in such patients. Caution is required in the use of DMARDs that are excreted primarily by the kidneys (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and antimalarial drugs), because glomerular filtration may be reduced in HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     HF management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of HF in patients with RA is similar to that in those without RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In terms of RA therapy, we suggest the immediate termination of anti-TNF agents, NSAIDs, and selective COX-2 inhibitors. In addition, we suggest that glucocorticoid therapy be reduced gradually to the lowest possible dose and discontinued when feasible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of developing heart failure (HF) is increased in patients with RA. The prevalence of echocardiographically determined LV systolic and both left and right ventricular diastolic dysfunction is also increased in this population. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology and pathogenesis of HF in RA are not well-understood. An increased prevalence of established risk factors (eg, hypertension, diabetes, dyslipidemia) may contribute, but RA itself appears to be an independent risk factor. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HF is made the same way in RA patients as in other patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Echocardiography should be performed in patients with RA who have signs or symptoms suggestive of HF. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Asymptomatic LV dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of HF in patients with RA includes interstitial lung disease and pericardial disorders. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiinflammatory and antirheumatic drug therapies may play a role in precipitating or exacerbating HF. These include anti-TNF agents, NSAIDs, COX-2 selective inhibitors, antimalarial drugs, and glucocorticoids. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antirheumatic drug therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Efforts to prevent HF in RA patients are focused on modifying traditional risk factors for HF and for ischemic heart disease, and on optimizing control of RA disease activity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link&amp;anchor=H18#H18\">",
"       \"Epidemiology and causes of heart failure\", section on 'Prevention of heart failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=see_link\">",
"       \"Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"       \"General principles of management of rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of HF is similar in patients with and without RA, but attention to the possible adverse cardiovascular effects of antiinflammatory and antirheumatic drug therapy may lead to additional diagnostic studies, such as endomyocardial biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cessation or gradual withdrawal of certain agents, particularly NSAIDs, COX-2 selective inhibitors, and glucocorticoids. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Avoiding exacerbation of HF'",
"      </a>",
"      above.) We recommend NOT using high-dose anti-TNF therapy in RA patients with a history of HF (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link&amp;anchor=H18#H18\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\", section on 'Heart failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest NOT administering anti-TNF therapy at any dose in patients with systolic LV dysfunction, independent of the presence or absence of symptoms (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antirheumatic drug therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, for patients with active RA whose arthritis is unresponsive to other DMARDs or biologic agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      ) and who have mild to moderate (NYHA functional class I or II) HF, use of an anti-TNF agent might be considered as an alternative to use of glucocorticoids. If anti-TNF therapy is used, we suggest cardiology consultation, lower doses of anti-TNF agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      &le;3",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      40 mg every two weeks, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/week),",
"      </span>",
"      and prompt discontinuation of anti-TNF therapy if HF worsens.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/1\">",
"      Voskuyl AE. The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45 Suppl 4:iv4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/2\">",
"      Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/3\">",
"      Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006; 54:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/4\">",
"      Crowson CS, Nicola PJ, Kremers HM, et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005; 52:3039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/5\">",
"      Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/6\">",
"      Bhatia GS, Sosin MD, Patel JV, et al. Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden? J Am Coll Cardiol 2006; 47:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/7\">",
"      Seyfeli E, Guler H, Akoglu S, et al. Right ventricular diastolic abnormalities in rheumatoid arthritis and its relationship with left ventricular and pulmonary involvement. A tissue Doppler echocardiographic study. Int J Cardiovasc Imaging 2006; 22:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/8\">",
"      Montecucco C, Gobbi G, Perlini S, et al. Impaired diastolic function in active rheumatoid arthritis. Relationship with disease duration. Clin Exp Rheumatol 1999; 17:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/9\">",
"      Corrao S, Sall&igrave; L, Arnone S, et al. Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest 1996; 26:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/10\">",
"      Di Franco M, Paradiso M, Mammarella A, et al. Diastolic function abnormalities in rheumatoid arthritis. Evaluation By echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis 2000; 59:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/11\">",
"      Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/12\">",
"      Rudominer RL, Roman MJ, Devereux RB, et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009; 60:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/13\">",
"      Giles JT, Malayeri AA, Fernandes V, et al. Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum 2010; 62:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/14\">",
"      Mutru O, Laakso M, Isom&auml;ki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/15\">",
"      Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/16\">",
"      Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 2007; 27:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/17\">",
"      Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006; 70:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/18\">",
"      Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/19\">",
"      Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/20\">",
"      Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/21\">",
"      Davis JM 3rd, Roger VL, Crowson CS, et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum 2008; 58:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/22\">",
"      Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/23\">",
"      Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26968/abstract/24\">",
"      Peters MJ, Welsh P, McInnes IB, et al. Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Ann Rheum Dis 2010; 69:1281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7493 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26968=[""].join("\n");
var outline_f26_21_26968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Population-based studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LV systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mortality due to heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antirheumatic drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Symptomatic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Asymptomatic LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Avoiding exacerbation of HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HF management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31433?source=related_link\">",
"      Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=related_link\">",
"      Echocardiographic evaluation of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20679?source=related_link\">",
"      Screening for asymptomatic left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_21_26969="Overview of lung disease associated with rheumatoid arthritis";
var content_f26_21_26969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of lung disease associated with rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26969/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26969/contributors\">",
"     Fiona R Lake, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26969/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26969/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/21/26969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid arthritis (RA) is a generally progressive systemic autoimmune process characterized by chronic symmetrical erosive synovitis. Nonarticular manifestations of RA include subcutaneous nodules, vasculitis, pericarditis, mononeuritis multiplex, and episcleritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/1\">",
"     1",
"    </a>",
"    ]. Pulmonary and pleural abnormalities are common in patients with RA, but may not result in significant symptoms. An overview of lung disease associated with RA will be presented here. Other aspects of RA, including specific causes of lung disease seen in patients with RA, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     \"Interstitial lung disease in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link\">",
"     \"Drug-induced lung disease in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of pleuropulmonary disease in patients with RA is broad [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The major causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rheumatoid-associated lung disease (",
"      <a class=\"graphic graphic_table graphicRef71641 \" href=\"UTD.htm?20/9/20636\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug-related lung disease secondary to drugs used to treat rheumatoid disease (",
"      <a class=\"graphic graphic_table graphicRef65141 \" href=\"UTD.htm?7/44/7885\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infection secondary to immunosuppression",
"     </li>",
"     <li>",
"      Coexistent medical conditions (eg, asthma, heart failure)",
"     </li>",
"     <li>",
"      Overlapping clinical syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of different types of pulmonary disease is difficult to estimate for a number of reasons. Patient populations have been heterogeneous among studies; examples include studies of patients with early versus late stage disease, and community versus hospital versus autopsy based studies. In addition, there is substantial variability in the sensitivity of tests used to define disease, ranging from analysis of pulmonary function to chest radiographs to high resolution computed tomography (HRCT). Finally, the subclinical nature of the disease in many patients has implications for disease surveillance, monitoring of abnormalities, and consideration of early preventive therapy, which may further complicate definitive epidemiologic assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link&amp;anchor=H2#H2\">",
"     \"Interstitial lung disease in rheumatoid arthritis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these limitations, it appears that interstitial lung disease (ILD) and pleural disease are most common; ILD, obliterative bronchiolitis (OB), drug reactions, and infections have the greatest impact on patient outcome. HLA associations have been correlated with the aggressiveness of joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/8\">",
"     8",
"    </a>",
"    ], but associations of HLA or clinical markers of disease with lung disease have not been recognized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=see_link\">",
"     \"HLA and other susceptibility genes in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERSTITIAL LUNG DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease is the most common manifestation of rheumatoid lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/5\">",
"     5",
"    </a>",
"    ]. The clinical presentation, pathology, disease spectrum, and pathogenesis of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) are similar to that of the idiopathic interstitial pneumonias (IIPs) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/2,3,9\">",
"     2,3,9",
"    </a>",
"    ]. Histologically, the abnormalities are highly variable but usually resemble one of the IIPs (",
"    <a class=\"graphic graphic_table graphicRef71641 \" href=\"UTD.htm?20/9/20636\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Usual interstitial pneumonia (UIP)",
"     </li>",
"     <li>",
"      Nonspecific interstitial pneumonia (NSIP)",
"     </li>",
"     <li>",
"      Organizing pneumonia",
"     </li>",
"     <li>",
"      Lymphocytic interstitial pneumonia(LIP)",
"     </li>",
"     <li>",
"      Desquamative interstitial pneumonia (DIP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    UIP and NSIP are most common, while organizing pneumonia, LIP, and DIP are seen less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The evaluation and management of ILD in RA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"     \"Interstitial lung disease in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=see_link\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ORGANIZING PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organizing pneumonia (OP, also known as bronchiolitis obliterans organizing pneumonia [BOOP] or cryptogenic organizing pneumonitis [COP]) is a proliferative bronchiolitis. It is frequently idiopathic, but can occur in response to infectious and toxic injuries. A number of studies have noted an association of OP with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In a study of open lung biopsies from 40 patients with parenchymal lung disease and RA, OP was the second most common pathologic manifestation, following rheumatoid nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/10\">",
"     10",
"    </a>",
"    ]. In other series it was the most common ILD after UIP and NSIP [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link\">",
"     \"Cryptogenic organizing pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RA complicated by OP present with cough, dyspnea, malaise, weight loss, and fever. Crackles are noted on physical examination. Laboratory and radiologic testing reveals the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The erythrocyte sedimentation rate (ESR) is usually elevated",
"     </li>",
"     <li>",
"      Chest radiograph shows bilateral parenchymal opacities, often with preserved lung volumes",
"     </li>",
"     <li>",
"      Lung physiology demonstrates a restrictive picture, with a decreased DLCO and hypoxemia",
"     </li>",
"     <li>",
"      HRCT shows unilateral or bilateral consolidation that is patchy and often peripheral (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81785 \" href=\"UTD.htm?2/48/2818\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnosis may occasionally be made with a transbronchial lung biopsy, but more commonly an open or thoracoscopic lung biopsy is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biopsy demonstrates patchy intraluminal polypoid plugs of immature fibroblast tissue within respiratory bronchioles. Terminal bronchioles and peribronchiolar alveolar spaces may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/10,17\">",
"     10,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H2#H2\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H2124602#H2124602\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Surgical lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of OP is generally good in patients with RA who receive treatment; however, spontaneous improvement is rare and rapid progression has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/18\">",
"     18",
"    </a>",
"    ]. Most patients with OP respond rapidly to oral glucocorticoid therapy; antibiotics are not helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is usually initiated with one to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (using ideal body weight) to a maximum of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given as a single oral dose in the morning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=see_link&amp;anchor=H12#H12\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend maintaining this dose for four to eight weeks. If the patient is stable or improved, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose is gradually tapered to 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (using ideal body weight) for the ensuing four to six weeks. High-dose parenteral glucocorticoid therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    125 to 250 mg every six hours intravenously for three to five days) is recommended as the initial treatment in patients with rapidly progressive severe disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is gradually tapered to zero if the patient remains stable or improved after three to six months. The patient should be routinely followed with chest radiographs and pulmonary function testing every six to eight weeks during the first year, and therapy should be reinstituted aggressively at the sign of any recurrence. Importantly, the chest radiograph may change before the patient develops significant symptoms.",
"   </p>",
"   <p>",
"    If the patient cannot tolerate glucocorticoid therapy, or deteriorates despite treatment, a cytotoxic agent should be started, maintaining low-dose (0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) oral glucocorticoid therapy if possible. We generally use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in this setting. The recommended dose is one to two",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (given as a single daily dose), although the optimal dose in OP is unknown. We usually start at 50 mg daily and slowly increase the dose over two to four weeks. We do not recommend exceeding 150",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    A trial of at least three to six months is needed to ensure an adequate opportunity for clinical response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematologic alterations are common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy and frequently necessitate dose adjustment; the total white blood cell count should be maintained above",
"    <span class=\"nowrap\">",
"     4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Leukopenia is the most common manifestation of hematologic toxicity, with anemia and thrombocytopenia occurring less often. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PLEURAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural disease is common in patients with RA, but it is usually subclinical [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/20\">",
"     20",
"    </a>",
"    ]. As an example, autopsy studies identified pleural disease in 38 to 73 percent of patients with RA, but only 5 to 21 percent had complained of pleurisy and just over 5 percent had radiologic evidence of a pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/3,9,21\">",
"     3,9,21",
"    </a>",
"    ]. Pleural disease is most common in patients with longstanding RA, but can precede joint disease. In addition, it is more common in men and coexists with rheumatoid nodules and ILD in up to 30 percent of patients (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55932 \" href=\"UTD.htm?35/18/36143\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When symptoms or signs occur, chest pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fever are most common. Patients with significant pleural effusions may report dyspnea. Physical examination may reveal a pleural rub, and there may be unilateral or bilateral effusions.",
"   </p>",
"   <p>",
"    Pleural abnormalities include exudative effusion, empyema, bronchopleural fistula, or pyopneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. Pleural effusion can be caused by necrosis and cavitation of a nodule into the pleural space [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/22\">",
"     22",
"    </a>",
"    ]. Chronic pleural thickening can cause chyliform effusions or lung entrapment, which may require decortication (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74857 graphicRef63153 \" href=\"UTD.htm?18/42/19110\">",
"     image 3A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thoracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracentesis should be performed in patients who have RA and a pleural effusion. The purpose of pleural fluid analysis is to confirm that the pleural fluid is an exudate and to rule out alternative etiologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural fluid analysis typically reveals a white cell count",
"    <span class=\"nowrap\">",
"     &lt;5000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ,",
"    </span>",
"    a pleural fluid glucose to serum glucose ratio less than 0.5, a pH less than 7.3, and high pleural fluid LDH level (ie, greater than 700",
"    <span class=\"nowrap\">",
"     IU/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef77436 \" href=\"UTD.htm?10/17/10524\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/3,20,21\">",
"     3,20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\", section on 'Chemical analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly, patients with RA and a long-standing pleural effusion will have a cholesterol effusion (also known as a pseudochylous or chyliform effusion), diagnosed by the appearance and analysis of the pleural fluid. Cholesterol effusions have the appearance of an empyema, but are sterile [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/20\">",
"     20",
"    </a>",
"    ]. The milky appearance is due to an elevated cholesterol level (always above 65",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and sometimes over 1000",
"    <span class=\"nowrap\">",
"     mg/dL);",
"    </span>",
"    cholesterol crystals, identifiable with polarized light, may also be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31448?source=see_link\">",
"     \"Clinical presentation, diagnosis and management of cholesterol effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empyema due to infection has similar pleural fluid characteristics and should be excluded by gram stain and culture, particularly in patients taking glucocorticoids.",
"   </p>",
"   <p>",
"    Cytologic examination of rheumatoid pleural fluid often reveals characteristic findings of slender or elongated multinucleated macrophages, round giant multinucleated macrophages, and necrotic background debris [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the specificity of these findings has not been fully evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/20\">",
"     20",
"    </a>",
"    ]. The presence of ragocytes, also known as \"RA cells\" is neither sensitive nor specific.",
"   </p>",
"   <p>",
"    A pleural biopsy may be helpful in excluding other disorders, such as tuberculosis or malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\", section on 'Pleural biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid pleuritis and pleural effusions usually do not require specific treatment as they commonly resolve spontaneously, between 1 and 36 months (mean 14 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/20\">",
"     20",
"    </a>",
"    ]. Several therapies have been reported to be useful including non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids (oral or intrapleural), pleurodesis, and decortication. The evidence for these treatments is mixed, but we would recommend starting with the least toxic. When treatment is needed because of pleuritic chest pain or the size of the effusion, the initial choice is an NSAID, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal therapy for patients who do not respond to a course of oral NSAID therapy is not clear. Local and systemic glucocorticoid therapy and treatment of rheumatoid joint disease with disease modifying agents (DMARDs) have all been tried with variable success in patients with a sterile rheumatoid empyema. Sometimes, the pleural effusion will resolve with treatment of rheumatoid joint disease.",
"   </p>",
"   <p>",
"    If the pleural effusion is refractory, we use a moderate dose of oral glucocorticoids. According to case reports, oral glucocorticoid therapy at a moderate dose (eg, 10 to 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    daily) may be beneficial. Following improvement, in our opinion, the glucocorticoids should be withdrawn slowly to prevent relapse. If the patient is intolerant of the side effects of systemic glucocorticoid, we administer intrapleural glucocorticoids (eg, 120 to 160 mg of depo-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    acetate) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/20,24\">",
"     20,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of chemical pleurodesis and decortication have also been reported, but are reserved for refractory effusions and fibrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of pulmonary infection in patients with RA varies substantially among studies. There is some suggestion that the incidence of infection is similar to that in the general population, but when infection is present in patients with RA, it results in higher morbidity and mortality. Abnormalities include pneumonia, bronchiectasis, empyema, and infected nodules. Suspected predisposing factors for pulmonary infections include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Underlying lung disease",
"     </li>",
"     <li>",
"      Host defense abnormalities (eg, poorly defined lymphocyte abnormalities)",
"     </li>",
"     <li>",
"      Immunosuppressive drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical signs of infection can be altered, since fever and leukocytosis may not be present because of immunosuppressive therapy. Treatment does not differ from that used in the general population. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     AIRWAY OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both upper and lower airway disease have been reported in patients with RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper airway disease is more common in women and in patients with long-standing RA. Direct laryngoscopy and CT scanning demonstrate that 54 to 75 percent of patients have cricoarytenoid abnormalities, although symptoms are reported in only about half this number [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/7\">",
"     7",
"    </a>",
"    ]. Laryngeal obstruction is usually related to ankylosis of the cricoarytenoid joints. Less commonly, a rheumatoid nodule on the vocal cord or vasculitis involving the recurrent laryngeal or vagus nerves may cause obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early symptoms of upper airway disease may include a hoarse voice, odynophagia, tenderness of the throat, pain on coughing or speaking, or exertional dyspnea. However, symptoms usually are absent until significant obstruction occurs. Thus, patients may present as an emergency with previously unsuspected disease when airway edema secondary to an infection or intubation causes life-threatening obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"     \"Diagnosis and management of central airway obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis of upper airway obstruction is made by laryngoscopy and inspiratory and expiratory flow volume loops (",
"    <a class=\"graphic graphic_figure graphicRef60463 \" href=\"UTD.htm?37/27/38332\">",
"     figure 1",
"    </a>",
"    ); an EMG may be required to differentiate nerve from joint disease. Flow volume loops demonstrate more marked limitation of inspiratory flow, but changes may not be present until the obstruction is severe. Because RA can be complicated by cervical spine instability, intubation and invasive diagnostic procedures should be performed without excessive neck flexion by experienced operators. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=see_link\">",
"     \"Cervical subluxation in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=see_link\">",
"     \"Flow-volume loops\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of tenderness of the throat or pain on coughing or speaking involves use of NSAIDs. Laryngoscopy usually is indicated for diagnosis; a tracheostomy may be necessary to bypass the obstruction and can be reversed at a later date. Surgical intervention with mobilization of the cricoarytenoid joints and lateral fixation of one of the cords has been reported in cases of severe obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. In an emergency, severe obstruction may respond to inhalation of helium-oxygen mixtures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link\">",
"     \"Physiology and clinical use of heliox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Small airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of small airway obstruction and bronchial hyperresponsiveness in patients with RA remains controversial, and studies have been confounded by the presence of smoking or RA-ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Initial reports suggested up to a 60 percent prevalence of airflow obstruction in patients with RA; later studies in non-smoking subjects noted a prevalence of 0 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Furthermore, the prevalence of small airways abnormalities on high resolution computed tomography (HRCT) is greater than that of physiologic airway obstruction detected by pulmonary function testing. In a study of patients with RA and without evidence of ILD, changes of small airways disease were noted on HRCT in 35 of 50 patients (70 percent). In patients with a normal HRCT, there were no physiological abnormalities; however, the HRCT was abnormal in 20 of 33 patients (60 percent) with normal physiology [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One review found an association with underlying Sj&ouml;gren's syndrome and histological changes of a peribronchiolar lymphocytic infiltrate in 6 patients with RA and documented airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/29\">",
"     29",
"    </a>",
"    ]. However, another study found no correlation between small airways obstruction and Sj&ouml;gren's syndrome, smoking history, or RA disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/28\">",
"     28",
"    </a>",
"    ]; it is likely that a variety of types of pathology contribute to airway obstruction.",
"   </p>",
"   <p>",
"    Treatment is similar to that used for airflow obstruction in other settings. No treatment is required in patients with mild disease, whereas inhaled bronchodilators, glucocorticoids, and occasionally a trial of oral glucocorticoids are used in those with symptomatic obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Obliterative bronchiolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obliterative bronchiolitis (OB) is a rare, usually fatal, condition characterized by progressive concentric narrowing of membranous bronchioles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    .) It was first reported in patients with RA in association with d-penicillamine treatment. OB has subsequently been noted with the use of gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , and in patients not receiving drug therapy (",
"    <a class=\"graphic graphic_table graphicRef65141 \" href=\"UTD.htm?7/44/7885\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. OB is more common in women, patients with positive rheumatoid factor tests, and in one series in association with Sj&ouml;gren's syndrome.",
"   </p>",
"   <p>",
"    OB usually follows the onset of joint symptoms. However, it has been reported in the setting of a high serum rheumatoid factor with no joint disease, suggesting it was the lone manifestation of rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically present with the rapid onset of dyspnea and dry cough [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/33\">",
"     33",
"    </a>",
"    ]. The rapidity of onset and severity of symptoms are out of keeping with most other forms of lung disease and should lead to suspicion of the diagnosis. Manifestations suggestive of OP, including fever, weight loss, and malaise, are generally not present. Findings on physical examination include inspiratory crackles and a classical mid-inspiratory squeak.",
"   </p>",
"   <p>",
"    Laboratory and radiologic investigations demonstrate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airflow obstruction, normal DLCO, and hypoxemia on testing of pulmonary function and arterial blood gases",
"     </li>",
"     <li>",
"      A normal chest radiograph or hyperinflation",
"     </li>",
"     <li>",
"      Bronchial wall thickening, centrilobular emphysema, areas of low attenuation with a mosaic pattern, and bronchiectasis may be seen on HRCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pathologic findings on transbronchial or open lung biopsy include constrictive bronchiolitis with lymphocytic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis and response to therapy are poor. Nevertheless, a trial of high dose glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) is warranted. The roles of long-term macrolide antibiotic treatment and immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , or a tumor necrosis factor alpha inhibitor are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link&amp;anchor=H15#H15\">",
"     \"Bronchiolitis in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A discussion of obliterative bronchiolitis following lung transplantation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bronchiectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between bronchiectasis and rheumatoid arthritis has been noted, although the prevalence in case series has varied from 0 to 10 percent. In a HRCT study of patients with rheumatoid arthritis, 30 percent were noted to have bronchiectasis without evidence of ILD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One small study noted that 16 percent of patients with RA and diffuse bronchiectasis were heterozygous for the delta F508 mutation of the cystic fibrosis transmembrane conductance regulator gene (CFTR), which was significantly higher than in a control group of patients with RA but no bronchiectasis (0 percent) and in the population at large (2.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/36\">",
"     36",
"    </a>",
"    ]. No alterations in sweat chloride concentration or nasal potential difference measurements were noted in heterozygotes, but CFTR abnormalities may predispose to the development of bronchiectasis in RA.",
"   </p>",
"   <p>",
"    Bronchiectasis does not appear to be clinically significant in most patients with RA. In those that require therapy, treatment should be similar to that used for other forms of bronchiectasis, including some combination of antibiotics, bronchodilators, and possibly antiinflammatory agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RHEUMATOID NODULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheumatoid nodules are the only pulmonary manifestation specific for RA. The prevalence of pulmonary rheumatoid nodules is not clear. Only 2 of 516 patients were noted to have nodules radiologically in one clinical series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/9\">",
"     9",
"    </a>",
"    ]. However, a study of open lung biopsies from 40 patients with suspected lung disease found that rheumatoid nodules were the most common abnormality, present in 13 subjects (32 percent); in 8 of 13 patients, there were multiple nodules [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/10\">",
"     10",
"    </a>",
"    ]. Only one patient subsequently developed any complication related to the nodule.",
"   </p>",
"   <p>",
"    Nodules are generally located in subpleural areas or in association with interlobular septa. Histologically, the pulmonary nodules are similar to nodules at other sites, with central necrosis, palisading epithelioid cells, a mononuclear cell infiltrate, and associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=see_link\">",
"     \"Rheumatoid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary rheumatoid nodules are generally asymptomatic, but can lead to complications including pleural effusion, pneumothorax, pyopneumothorax, bronchopleural fistula, hemoptysis, and infection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55932 \" href=\"UTD.htm?35/18/36143\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67705 \" href=\"UTD.htm?40/25/41374\">",
"     image 4",
"    </a>",
"    ). However, the prognosis is generally good, with spontaneous resolution and infrequent complications.",
"   </p>",
"   <p>",
"    It is recommended that asymptomatic nodules be followed with a repeat chest radiograph, as the main alternative in the differential diagnosis is an underlying malignancy, particularly when only a single lesion is present. Depending upon the clinical circumstances, fine needle aspiration may need to be performed to exclude the possibility of malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Caplan's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caplan's syndrome occurs only in patients with both rheumatoid arthritis and pneumoconiosis related to mining dust (coal, asbestos, silica) exposure. The syndrome is characterized by rapid development of multiple peripheral basilar nodules in association with mild airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Caplan's syndrome can be complicated by the development of progressive massive fibrosis (PMF); however, patients with rheumatoid arthritis are at no greater risk of developing PMF than are other subjects exposed to mining dust. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33145?source=see_link\">",
"     \"Silicosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically, the findings are similar to those with simple rheumatoid nodules, except that the nodules in Caplan's syndrome are surrounded by pigmented cells. This abnormality has most commonly been reported in Europe and is rare in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. There is no effective treatment for Caplan's syndrome, but the prognosis is good.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VASCULITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is a well-recognized extraarticular manifestation of RA presenting with skin ulcers and mononeuritis multiplex. Primary vasculitic involvement of the lung is uncommon, although pathologic evidence of vasculitis is an inherent feature of rheumatoid nodules at all sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42407?source=see_link\">",
"     \"Epidemiology and pathogenesis of rheumatoid vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other lung disease associated with RA include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Apical fibrobullous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical fibrotic and cavitary lesions similar to those in ankylosing spondylitis have been reported in patients with RA. In cases where the pathology was available, unsuspected necrobiotic nodules appeared to be the cause [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H3#H3\">",
"     \"Diseases of the chest wall\", section on 'Ankylosing spondylitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thoracic cage immobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of thoracic cage mobility, again similar to those seen with ankylosing spondylitis, have been reported and suggested to be associated with pleurisy, myopathy, and thoracic rigidity. Pulmonary function testing demonstrates a low total lung capacity with a low or normal DLCO and a high",
"    <span class=\"nowrap\">",
"     DL/Va",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H3#H3\">",
"     \"Diseases of the chest wall\", section on 'Ankylosing spondylitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic pulmonary arterial hypertension is rare in patients with RA. It is thought to be related to an underlying vasculitis, and signs of a systemic vasculitis are often present simultaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/4,38\">",
"     4,38",
"    </a>",
"    ]. The clinical manifestations and prognosis are very similar to those with idiopathic pulmonary arterial hypertension in the absence of RA. Secondary pulmonary hypertension has also been reported in patients with RA; this is usually seen in association with severe ILD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing lung cancer may be slightly greater in patients with RA than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/4,39-41\">",
"     4,39-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MONITORING FOR LUNG DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surveillance for lung disease in patients with RA is not clear, since minor abnormalities of unclear clinical significance are common, the natural history and prognosis of the disorder are variable, and the role of therapy is uncertain. Early disease detection may be important in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in whom life-threatening deterioration occurs (eg, upper airways obstruction due to cricoarytenoid disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with preexisting disease who may have increased morbidity if a pulmonary-related drug reaction occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26969/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Possibly in cases for which histopathologic evidence suggests that early treatment could be beneficial (eg, RA-ILD when inflammatory rather than fibrotic disease is present). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link&amp;anchor=H11#H11\">",
"       \"Interstitial lung disease in rheumatoid arthritis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a thorough history and examination for pulmonary symptoms and signs should be performed in all patients, particularly focusing on subtle changes that might be due to upper airways disease, which can be devastating if a general anesthetic is planned. When abnormalities are found, further investigations are likely to be required to define the process. Serial history, physical examination, and lung function measurements should be used to monitor the progression of disease. Similarly, when drugs with potentially toxic effects are being considered, symptoms and signs of underlying parenchymal disease should be sought. We also recommend that a chest radiograph and measurement of lung function (including DLCO) be performed in this circumstance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link\">",
"     \"Drug-induced lung disease in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, based on some evidence that treatment may be beneficial in asymptomatic ILD, investigation such as HRCT and bronchoalveolar lavage (BAL), which are more sensitive than symptoms and signs alone, could be considered. This approach, however, is controversial, and it is appropriate to await further studies defining the natural history of abnormalities detected with these tests as well as the most cost-effective diagnostic approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients with rheumatoid arthritis presenting with respiratory symptoms needs to take into account multiple possible causes, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rheumatoid-associated lung disease (",
"      <a class=\"graphic graphic_table graphicRef71641 \" href=\"UTD.htm?20/9/20636\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Drug-related lung disease secondary to drugs used to treat rheumatoid disease (",
"      <a class=\"graphic graphic_table graphicRef65141 \" href=\"UTD.htm?7/44/7885\">",
"       table 2",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link\">",
"       \"Drug-induced lung disease in rheumatoid arthritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infection secondary to immunosuppression",
"     </li>",
"     <li>",
"      Coexistent medical disease (eg, asthma, COPD, heart failure)",
"     </li>",
"     <li>",
"      Overlapping clinical syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A thorough history and physical examination, including a search for extrapulmonary signs of disease, may suggest the underlying diagnosis. Initial laboratory and diagnostic testing frequently includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential (looking for neutrophilia in cases of infection and eosinophilia in drug reactions)",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Blood cultures",
"     </li>",
"     <li>",
"      Sputum culture (bacterial, mycobacterial, fungal)",
"     </li>",
"     <li>",
"      Pulmonary function assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"       \"Overview of pulmonary function testing in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      spirometry, lung volumes, diffusing capacity (DLCO)",
"     </li>",
"     <li>",
"      inspiratory and expiratory flow volume curves",
"     </li>",
"     <li>",
"      exercise testing to detect desaturation (may be limited by joint disease)",
"     </li>",
"     <li>",
"      arterial blood gases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conventional chest radiograph &ndash; frequently normal despite symptoms",
"     </li>",
"     <li>",
"      High resolution computed tomography (HRCT) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Interstitial lung disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Organizing pneumonia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Diagnostic thoracentesis if a pleural effusion is present. (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Pleural disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"       \"Diagnostic thoracentesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"       \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evaluation is based on the results of initial testing. The following topic reviews may be helpful in guiding the evaluation.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=see_link\">",
"       \"Interstitial lung disease in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=see_link\">",
"       \"Drug-induced lung disease in rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"       \"Methotrexate-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"       \"Bronchiolitis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"       \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=see_link\">",
"       \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Wilder RL. Rheumatoid arthritis. A. Epidemiology, Pathology, and pathogenesis. In: Primer on the rheumatic diseases, 10th ed, Schumacher HR (Ed), Arthritis Foundation, Atlanta 1993.",
"    </li>",
"    <li>",
"     Freemer MM, King TE Jr. Connective tissue disease. In: Interstitial Lung Disease, 4th ed, King TE Jr, Schwarz MI (Eds), B.C. Decker, Hamilton, ON, Canada 2003. p.536.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/3\">",
"      Kelly CA. Rheumatoid arthritis: classical rheumatoid lung disease. Baillieres Clin Rheumatol 1993; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/4\">",
"      Kelly CA. Rheumatoid arthritis: other rheumatoid lung problems. Baillieres Clin Rheumatol 1993; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/5\">",
"      Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998; 19:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/6\">",
"      Wallaert B, Hatron PY, Grosbois JM, et al. Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis 1986; 133:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/7\">",
"      Geterud A, Ejnell H, M&aring;nsson I, et al. Severe airway obstruction caused by laryngeal rheumatoid arthritis. J Rheumatol 1986; 13:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/8\">",
"      Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995; 95:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/9\">",
"      Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine (Baltimore) 1968; 47:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/10\">",
"      Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985; 131:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/11\">",
"      Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/12\">",
"      Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/13\">",
"      Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. Rheumatol Int 2005; 26:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/14\">",
"      Rees JH, Woodhead MA, Sheppard MN, du Bois RM. Rheumatoid arthritis and cryptogenic organising pneumonitis. Respir Med 1991; 85:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/15\">",
"      Ippolito JA, Palmer L, Spector S, et al. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Semin Arthritis Rheum 1993; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/16\">",
"      van Thiel RJ, van der Burg S, Groote AD, et al. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Eur Respir J 1991; 4:905.",
"     </a>",
"    </li>",
"    <li>",
"     Colby TV. Lung Pathology. In: The Lung in Rheumatic Diseases, Cannon G, Zimmermann G (Eds), Marcel Dekker, New York 1990. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/18\">",
"      Cohen AJ, King TE Jr, Downey GP. Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med 1994; 149:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/19\">",
"      Gilligan DM, O'Connor CM, Ward K, et al. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax 1990; 45:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/20\">",
"      Balbir-Gurman A, Yigla M, Nahir AM, Braun-Moscovici Y. Rheumatoid pleural effusion. Semin Arthritis Rheum 2006; 35:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/21\">",
"      Sahn, SA. Pathogenesis of pleural effusions and pleural lesions. In: The lung in rheumatic diseases, Cannon, GW, Zimmerman, GA (Eds), Lung Biology in Health and Disease 1990; 45:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/22\">",
"      Jacobs TE, Hollingsworth HM, Nash G. Persistent bilateral effusions and fever in a 48-year-old man. Chest 1993; 104:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/23\">",
"      Avnon LS, Abu-Shakra M, Flusser D, et al. Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate? Rheumatol Int 2007; 27:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/24\">",
"      Chapman PT, O'Donnell JL, Moller PW. Rheumatoid pleural effusion: response to intrapleural corticosteroid. J Rheumatol 1992; 19:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/25\">",
"      Hassan WU, Keaney NP, Holland CD, Kelly CA. Bronchial reactivity and airflow obstruction in rheumatoid arthritis. Ann Rheum Dis 1994; 53:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/26\">",
"      Fuld JP, Johnson MK, Cotton MM, et al. A longitudinal study of lung function in nonsmoking patients with rheumatoid arthritis. Chest 2003; 124:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/27\">",
"      Sassoon CS, McAlpine SW, Tashkin DP, et al. Small airways function in nonsmokers with rheumatoid arthritis. Arthritis Rheum 1984; 27:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/28\">",
"      Perez T, Remy-Jardin M, Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998; 157:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/29\">",
"      B&eacute;gin R, Mass&eacute; S, Cantin A, et al. Airway disease in a subset of nonsmoking rheumatoid patients. Characterization of the disease and evidence for an autoimmune pathogenesis. Am J Med 1982; 72:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/30\">",
"      Geddes DM, Corrin B, Brewerton DA, et al. Progressive airway obliteration in adults and its association with rheumatoid disease. Q J Med 1977; 46:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/31\">",
"      Cannon GW. Antirheumatic drug reactions in the lung. Baillieres Clin Rheumatol 1993; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/32\">",
"      Schwarz MI, Lynch DA, Tuder R. Bronchiolitis obliterans: the lone manifestation of rheumatoid arthritis? Eur Respir J 1994; 7:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/33\">",
"      Devouassoux G, Cottin V, Liot&eacute; H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009; 33:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/34\">",
"      M&uuml;ller NL, Miller RR. Diseases of the bronchioles: CT and histopathologic findings. Radiology 1995; 196:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/35\">",
"      Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994; 193:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/36\">",
"      Pu&eacute;chal X, Fajac I, Bienvenu T, et al. Increased frequency of cystic fibrosis deltaF508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J 1999; 13:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/37\">",
"      Yue CC, Park CH, Kushner I. Apical fibrocavitary lesions of the lung in rheumatoid arthritis. Report of two cases and review of the literature. Am J Med 1986; 81:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/38\">",
"      Sharma S, Vaccharajani A, Mandke J. Severe pulmonary hypertension in rheumatoid arthritis. Int J Cardiol 1990; 26:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/39\">",
"      Yang Y, Fujita J, Tokuda M, et al. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 2001; 21:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/40\">",
"      Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy--is there an association? Scand J Rheumatol 2001; 30:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/41\">",
"      Khurana R, Wolf R, Berney S, et al. Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 2008; 35:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26969/abstract/42\">",
"      Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22:1043.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4380 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26969=[""].join("\n");
var outline_f26_21_26969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERSTITIAL LUNG DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ORGANIZING PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PLEURAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AIRWAY OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Small airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Obliterative bronchiolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bronchiectasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RHEUMATOID NODULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Caplan's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VASCULITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Apical fibrobullous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thoracic cage immobility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MONITORING FOR LUNG DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4380|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/48/2818\" title=\"diagnostic image 1\">",
"      Cryptogenic organizing pneumonia CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/18/36143\" title=\"diagnostic image 2\">",
"      Rheumatoid nodule CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/46/26336\" title=\"diagnostic image 3A\">",
"      Rheumatoid pleural disease chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/57/33681\" title=\"diagnostic image 3B\">",
"      Rheumatoid pleural disease CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/25/41374\" title=\"diagnostic image 4\">",
"      Rheumatoid nodule chest xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4380|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/27/38332\" title=\"figure 1\">",
"      Vocal cord palsy flow volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/9/20636\" title=\"table 1\">",
"      Respiratory disease and RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/44/7885\" title=\"table 2\">",
"      Respiratory disease from RA drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/17/10524\" title=\"table 3\">",
"      Rheumatoid pleural effusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41080?source=related_link\">",
"      Cervical subluxation in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=related_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20697?source=related_link\">",
"      Clinical manifestations and diagnosis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31448?source=related_link\">",
"      Clinical presentation, diagnosis and management of cholesterol effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30344?source=related_link\">",
"      Drug-induced lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/26/42407?source=related_link\">",
"      Epidemiology and pathogenesis of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25878?source=related_link\">",
"      Flow-volume loops",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23546?source=related_link\">",
"      HLA and other susceptibility genes in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17912?source=related_link\">",
"      Interstitial lung disease in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29815?source=related_link\">",
"      Rheumatoid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33145?source=related_link\">",
"      Silicosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_21_26970="Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome";
var content_f26_21_26970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26970/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26970/contributors\">",
"     David Schiff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26970/contributors\">",
"     Paul Brown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26970/contributors\">",
"     Mark Edwin Shaffrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26970/contributors\">",
"     Jerome B Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/21/26970/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26970/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/21/26970/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/21/26970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplastic epidural spinal cord compression (ESCC) is a common complication of cancer that can cause pain and potentially irreversible loss of neurologic function. Although the degree of thecal sac compression required for the designation of ESCC has been variably defined, we consider any radiologic evidence of indentation of the thecal sac to be evidence for ESCC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prognosis of ESCC are discussed here. The clinical features and diagnostic approach to patients with possible ESCC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment for patients with ESCC include pain control, avoidance of complications, and the preservation or improvement of neurologic function utilizing treatments appropriate to the patient's burden of disease, life expectancy, and values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679514895\">",
"    <span class=\"h2\">",
"     Impact of treatment delay on posttreatment ambulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important prognostic factor for regaining ambulation after treatment of an ESCC is pretreatment neurologic status [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. In a review of 1392 patients presenting between 1963 and 1982, only 32 percent were ambulatory at the onset of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/12\">",
"     12",
"    </a>",
"    ]. Similar results were noted in a study published in 1998 in which only 33 percent of patients were ambulatory and 53 percent catheter-free at the time of therapy, indicating that little improvement had been made in the early detection of ESCC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/13\">",
"     13",
"    </a>",
"    ]. These patients had back pain for a median of two months before ESCC was diagnosed, and there was a 10-day delay between the onset of neurologic symptoms and the start of therapy. The majority of patients had deterioration of motor or bladder function during the delay.",
"   </p>",
"   <p>",
"    Thus, educating cancer patients and their families as well as responsible health care providers about symptoms that warrant immediate evaluation, particularly otherwise unexplained back pain, might improve neurologic outcomes. More recent data suggest that these numbers are improving; in a 2010 study, 62 percent of patients who presented with an ESCC were ambulatory at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     General principles of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with ESCC includes the immediate administration of glucocorticoids in all patients, followed by surgery, external beam radiation therapy (EBRT), or stereotactic body radiotherapy (SBRT). Systemic therapy may be beneficial in patients with chemosensitive tumors.",
"   </p>",
"   <p>",
"    Symptomatic treatment of ESCC often begins prior to definitive therapy and consists of the following general principles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain management &mdash; Patients with ESCC are frequently in severe pain, often limiting the ability to perform a thorough neurologic examination. Glucocorticoids usually improve the pain within several hours, but most patients require opiate analgesics to tolerate the physical examination and necessary diagnostic studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"       \"Cancer pain management with opioids: Optimizing analgesia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bedrest &mdash; There is generally no need to confine the patient to bed. Patients are generally quite adept at avoiding maneuvers that trigger their pain and there is no risk that movement will worsen the neurologic status.",
"     </li>",
"     <li>",
"      Anticoagulation &mdash; Patients with cancer are in a hypercoagulable state. Although the value of prophylaxis against venous thromboembolism has not been studied specifically in patients with ESCC, anticoagulation (ie, unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , low molecular weight heparin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      ) should be considered if the patient is immobilized due to the ESCC and there is no active bleeding or other contraindications to the use of anticoagulants.",
"      <br/>",
"      <br/>",
"      If surgery is planned in the immediate future, anticoagulation should be withheld. If there are contraindications to the use of anticoagulants, such patients should be treated with mechanical prophylaxis, such as pneumatic venous compression devices or graduated compression stockings. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"       \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention of constipation &mdash; Autonomic dysfunction from the spinal lesion, limited mobility, and opiate analgesics all can contribute to the development of constipation, ileus, and occasionally perforation of an abdominal viscus, the symptoms of which may be masked by glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/15\">",
"       15",
"      </a>",
"      ]. Consequently, an aggressive bowel regimen is indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=see_link&amp;anchor=H2#H2\">",
"       \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Bowel issues'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients with pain that is refractory to standard management, consideration should be given to kyphoplasty or vertebroplasty. (See",
"      <a class=\"local\" href=\"#H679516192\">",
"       'Vertebroplasty and kyphoplasty'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose corticosteroid therapy is generally considered to be part of the standard regimen for ESCC, despite limited documented evidence of benefit and a significant risk of serious side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/1,16,17\">",
"     1,16,17",
"    </a>",
"    ]. Several studies have suggested that lower doses can be effective but they have not been assessed in randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial actions of glucocorticoids in restoring neurologic function in patients with ESCC were first reported in the late 1960s. Animal studies documenting salutary effects in various models of ESCC soon followed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only three clinical trials have addressed the utility and optimal initial dose of glucocorticoids in ESCC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 57 patients with carcinoma (two-thirds with a primary in the breast) and myelographically confirmed ESCC were randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (96 mg intravenously followed by 24 mg four times daily for three days and then tapered over 10 days) or no dexamethasone [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/20\">",
"       20",
"      </a>",
"      ]. Stratification factors included primary tumor type and the extent of neurologic dysfunction; all patients received standardized RT.",
"      <br/>",
"      <br/>",
"      A significantly higher percentage of patients in the dexamethasone group remained ambulatory both at the conclusion of therapy (81 versus 63 percent) and at six months (59 versus 33 percent). Significant side effects were seen in three patients (11 percent in the steroid group). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal initial dose of steroids was addressed in a small trial in which 20 patients undergoing RT (30 Gy in 10 fractions) were randomly assigned to 96 or 16 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      daily for the first 48 hours, followed by a rapid taper over 15 days [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/22\">",
"       22",
"      </a>",
"      ]. The incidence of serious adverse events was five of nine in the high-dose and four of 11 in the low-dose group. There were no advantages for pain control or one month ambulation with high dose steroids.",
"     </li>",
"     <li>",
"      In another trial that attempted to identify the optimal corticosteroid dose, 37 patients with ESCC were randomly assigned to an initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      bolus of 10 mg or 100 mg intravenously, both followed by 16 mg daily orally [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/21\">",
"       21",
"      </a>",
"      ]. There were no differences in pain control or neurologic outcome between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Cochrane meta-analysis of these three studies concluded that the available data provided insufficient evidence as to the role of corticosteroids and the appropriate initial dose [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/16\">",
"     16",
"    </a>",
"    ]. When all three trials were considered, higher initial doses were not associated with better outcomes, but they were associated with a higher incidence of serious adverse events (such as perforated gastric ulcer, psychosis, and death from infection).",
"   </p>",
"   <p>",
"    The prominence of steroid-induced complications with higher initial doses was underscored in another uncontrolled series of 28 patients undergoing RT, all of whom were initially treated with 96 mg IV, tapering to off within 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/23\">",
"     23",
"    </a>",
"    ]. Side effects were noted in 28 percent, one-half of which were considered serious or life threatening. As a result, the high-dose regimen was abandoned and the initial dose was lowered to 16 mg daily tapered over two weeks; there were no serious side effects seen in 38 patients, and the ambulatory outcome was similar to that seen with higher dose therapy.",
"   </p>",
"   <p>",
"    It is uncertain if patients with less severe disease need steroid therapy. One small phase II trial showed that patients with back pain but no myelopathy and less than 50 percent narrowing of the spinal canal by epidural tumor could successfully undergo RT without receiving glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician has a choice between the \"high\" dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    with proven efficacy and a relatively high rate of serious side effects and a \"low\" dose with notably fewer side effects but no randomized controlled data to support its use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We reserve the high-dose regimen for patients with paraparesis or paraplegia and then halve the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    dose every three days. It is a reasonable alternative to treat these patients with a low-dose regimen based upon the available data suggesting therapeutic equivalence. Patients with pain but minimal neurologic dysfunction receive a bolus of 10 mg followed by 16 mg daily initially in divided doses. The dose is gradually tapered once definitive treatment is well underway. Patients with high-grade and symptomatic lesions likely need glucocorticoids even if they have relative contraindications. Patients with small epidural lesions without compression of the spinal cord and a normal neurologic examination may forgo the use of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679512095\">",
"    <span class=\"h2\">",
"     Definitive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of modality for definitive treatment depends on many factors, including the presence of absence of spinal instability, the degree of spinal cord compression, and the relative radiosensitivity of the tumor. An algorithmic approach to treatment based upon these factors is available (",
"    <a class=\"graphic graphic_algorithm graphicRef60269 \" href=\"UTD.htm?34/17/35102\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679515503\">",
"    <span class=\"h3\">",
"     Assessing spinal stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component of the decision making process when considering definitive therapy is assessment of spinal stability. Treatment of an ESCC differs in those patients whose spine is unstable compared to those with a stable spine. Pain from an unstable spine will not be relieved with radiotherapy, and there is a lack of evidence on whether spinal bracing is an effective technique for reducing pain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, an unstable spine must be stabilized either by surgery with fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/26\">",
"     26",
"    </a>",
"    ] or by percutaneous vertebral repair (in the absence of epidural disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been no widely accepted definition of what constitutes an unstable spine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/28\">",
"     28",
"    </a>",
"    ]. Systematic reviews of the available literature could not definitively describe what constitutes neoplastic spinal instability [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Older approaches to defining spinal instability relied mainly on clinical features (ie, a diagnosis of spinal instability can be made clinically if the patient has pain on motion that is not present at rest) with support from diagnostic imaging.",
"   </p>",
"   <p>",
"    A novel classification system for spinal instability in neoplastic disease has been developed based upon the available evidence and expert consensus opinion consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/31\">",
"     31",
"    </a>",
"    ]. Systematic reviews of the literature were performed to identify the best evidence for clinical, radiographic, and pathologic factors that relate to neoplastic spinal instability in the cervical and thoracolumbar spine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. These reviews served as the framework to guide expert consensus from the Spine Oncology Study Group, an international group of 30 spine oncology experts from around the world. By consensus, the highest ranked factors predictive of spinal instability included",
"    <span class=\"nowrap\">",
"     subluxation/translation,",
"    </span>",
"    progression of deformity, bilateral facet destruction, and character of neurologic changes (with motion). The anatomic areas of greatest concern were the occipitocervical junction and the cervicothoracic junction. Consensus opinion was used to derive six individual components of spinal instability, which were scored, with a final Spine Instability Neoplastic Score (SINS) representing a composite score of the individual components (",
"    <a class=\"graphic graphic_table graphicRef80396 \" href=\"UTD.htm?14/24/14733\">",
"     table 1",
"    </a>",
"    ). According to this classification, patients with a score of 7 or higher are considered to be at risk for spinal instability and warrant surgical consultation.",
"   </p>",
"   <p>",
"    The validity of the SINS was addressed in a cohort of 30 patients with spinal tumors that were classified as stable, potentially unstable, and unstable by members of the Spine Oncology Study Group (the same group that devised the classification scheme) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/32\">",
"     32",
"    </a>",
"    ]. The sensitivity and specificity rates of SINS for potentially unstable or unstable lesions were 96 and 80 percent, respectively. In addition, there was &ldquo;near-perfect&rdquo; inter- and intraobserver reliability in determining the three clinically relevant categories of stability.",
"   </p>",
"   <p>",
"    While the published evidence was considered in deriving the SINS, this classification system is not evidence based and it reflects broad expert opinion of spinal neurosurgeons. In addition, it lacks independent prospective validation. Nevertheless, it represents a contemporary consensus approach to defining spinal instability. Regardless of the radiographic findings, the clinician should consider every patient with pain caused by movement to be unstable until proved otherwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many years, posterior decompression using a laminectomy for patients with ESCC was the initial approach in the patient with neurologic compromise. However, retrospective comparisons of case series of patients treated with laminectomy with or without RT versus RT alone revealed no advantage to the surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/12\">",
"     12",
"    </a>",
"    ]. An early small randomized trial found no difference in outcome between patients undergoing laminectomy followed by RT versus RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the bulk of tumor is usually located in the vertebral body anterior to the thecal sac, the failure of laminectomy to improve outcome substantially is not surprising. Decompressing the spine posteriorly provides little access to anterior tumor and may further destabilize the spine. Laminectomy without spine stabilization should be avoided, whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Radical resection followed by RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in surgical techniques led to the use of more aggressive tumor resections followed by spinal reconstruction if necessary for patients with ESCC. Promising results were obtained by curetting out the tumor from the vertebral body and epidural space, with anterior stabilization using either bone grafting or methylmethacrylate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. Methylmethacrylate has important advantages over bone grafting in view of the frequent need for postoperative RT, since RT can begin one week following methylmethacrylate but must be deferred for at least six weeks to allow for fusion after bone grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of integrating aggressive tumor debulking and stabilization into the initial management was shown in a randomized trial that compared direct circumferential surgical decompression followed by RT (30 Gy over 10 days, starting within 14 days of surgery) with the same RT alone in 101 patients with metastatic ESCC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/37\">",
"     37",
"    </a>",
"    ]. Enrolled patients had a known cancer diagnosis (patients with lymphoma or a primary spine tumor were excluded), a single level of cord compression, and could not have been paraplegic for more than 48 hours. Both groups received the same initial dose of glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    100 mg initially, then 24 mg every six hours) and either began radiation or underwent surgery within 24 hours of presentation.",
"   </p>",
"   <p>",
"    The study was stopped after a planned interim analysis, which showed that patients treated with surgery followed by RT had a significantly higher ambulatory rate (84 versus 57 percent with to RT alone) and retained the ability to walk significantly longer than those treated with RT alone (median 122 versus 13 days). In addition, 10 of 16 patients who were initially unable to walk regained the ability to ambulate after surgery, compared to 3 of 16 treated with RT alone. Three of 10 patients who failed to respond to RT regained the ability to walk after salvage surgery. The use of glucocorticoids and opioid analgesics was also reduced in those treated surgically.",
"   </p>",
"   <p>",
"    A later unplanned subgroup analysis from this trial also suggested an important interaction between age and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/40\">",
"     40",
"    </a>",
"    ]. Preservation of ambulation was significantly prolonged in surgically treated patients under the age of 65, but not in older individuals. This association has not been found in other analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high complication rate is often observed in patients undergoing resection and stabilization after prior spine radiotherapy. In a series of 110 patients undergoing aggressive tumor resection for ESCC following RT, 47 of whom had failed to respond to prior irradiation and 44 percent of whom were nonambulatory [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/36\">",
"     36",
"    </a>",
"    ]. Postoperative complications occurred in 48 percent and were related statistically to age over 65 years, prior treatment, and presence of paraparesis.",
"   </p>",
"   <p>",
"    Others have questioned the role of surgery. A retrospective analysis compared outcomes among 108 patients receiving surgery plus RT and a matched cohort of 216 patients treated with RT alone; patients were matched for 11 potentially prognostic factors, including age, performance status, type of tumor, number of involved vertebrae, presence of other bone or visceral metastases at the time of RT, ambulatory status prior to RT, duration of motor deficits prior to RT, and the specific RT regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/14\">",
"     14",
"    </a>",
"    ]. All evaluated outcomes were similar in the two groups, including improvement of motor function (27 versus 26 percent for surgery plus RT versus RT alone), posttreatment ambulatory rate (69 versus 68 percent), regaining the ability to walk (30 versus 26 percent), and local control rates (90 versus 91 percent). The surgical complication rate was 11 percent. &nbsp;",
"   </p>",
"   <p>",
"    These data suggest that additional larger randomized trials comparing resection plus RT versus RT alone with stratification according to known prognostic factors are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679516192\">",
"    <span class=\"h4\">",
"     Vertebroplasty and kyphoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an unstable spine who are not candidates for radical surgery may derive some symptomatic benefit from minimally invasive techniques such as vertebroplasty and kyphoplasty, followed by EBRT. We reserve this approach for patients with symptomatic spinal metastases without epidural disease or retropulsion of bone fragments into the spinal cord. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=see_link&amp;anchor=H380436962#H380436962\">",
"     \"Cancer pain management: Interventional therapies\", section on 'Vertebroplasty and kyphoplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of a randomized trial indicate that radical resection and stabilization followed by RT increases the likelihood of regaining the ability to walk and of maintaining ambulation following treatment compared to those treated with RT alone. Careful selection is required to identify those patients with an adequate life expectancy and good medical status who are candidates for this aggressive approach [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/42\">",
"     42",
"    </a>",
"    ]. Although questions have been raised about the benefit of surgery, until further information is available from prospective randomized trials, suitable carefully selected patients should be offered the option of surgical resection. Surgical decompression is the preferred approach for patients with an unstable spine and for relatively radioresistant tumors that compress the spinal cord (",
"    <a class=\"graphic graphic_algorithm graphicRef60269 \" href=\"UTD.htm?34/17/35102\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     External beam RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the use of radical surgery, EBRT was the initial treatment of choice for most patients with ESCC. It is still used for patients who are not considered surgical candidates and following surgical decompression. The RT portal covers the width of the vertebral body and all areas of paravertebral tumor extension with margin, is centered on the spine, and typically extends one vertebral body above and below the epidural metastasis. The necessity of including the adjacent vertebrae in the radiation treatment volume has been questioned, given the low rates of local failure (&lt;5 percent) in adjacent unirradiated vertebral bodies in patients with isolated spinal metastases (without ESCC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/43\">",
"     43",
"    </a>",
"    ]); disadvantages of treating with just a margin on the disease (as opposed to one vertebral body above and below) include the difficulty in matching radiation fields if recurrences occur adjacent to the prior radiated field, the requirement of daily imaging when delivering EBRT with tighter margins, and the uncertainty of microscopic extent of disease once it has entered the epidural space.",
"   </p>",
"   <p>",
"    RT is generally very well tolerated. When large segments of the spine are irradiated, bone marrow suppression and gastrointestinal toxicity may complicate treatment. (See",
"    <a class=\"local\" href=\"#H679515190\">",
"     'Implications for survival'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679512734\">",
"    <span class=\"h4\">",
"     Response to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBRT is effective for palliation of pain and local tumor control [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/44\">",
"     44",
"    </a>",
"    ]. Approximately 70 percent of patients have an improvement in pain, and one-half of those without spinal instability experience resolution of back pain following EBRT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3,33,44,45\">",
"     3,33,44,45",
"    </a>",
"    ]. Local control rates are over 75 percent, and one study found that 58 percent of blocked myelograms returned to normal after RT for prostate cancer metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/5,45,46\">",
"     5,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in neurologic function is more variable. Pretreatment neurologic function is the strongest predictor of posttreatment neurologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. In most series, 67 to 82 percent of patients who are ambulatory when treated remain ambulatory at the conclusion of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3,44,47\">",
"     3,44,47",
"    </a>",
"    ]. Approximately one-third of patients who are nonambulatory because of paraparesis regain the ability to walk with treatment, as do 2 to 6 percent of those who are paraplegic; higher rates are reported in series with predominantly radiosensitive neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of being ambulatory after treatment is also higher among patients whose motor deficits developed more slowly (over longer than two weeks versus less than one week prior to therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/48\">",
"     48",
"    </a>",
"    ], and in nonambulatory patients, among those whose treatment is begun less than 12 hours after loss of ambulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/49\">",
"     49",
"    </a>",
"    ]. Among patients who require a urinary catheter before therapy, 20 to 40 percent will become catheter free [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the second major predictor of response in patients unable to walk is the underlying tumor type. Patients who are paraparetic or even paraplegic have a much better chance of recovery if they have a highly radiosensitive tumor such as lymphoma, myeloma, seminoma, small cell lung cancer (SCLC), and breast, prostate, or ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3,45,50,51\">",
"     3,45,50,51",
"    </a>",
"    ]. Patients with these histologies also are less likely to suffer local relapse of their epidural disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Patients with relatively radioresistant tumors (eg, melanoma, renal cell carcinoma, sarcoma, possibly non-small cell lung cancer) are better approached with high-dose stereotactic radiosurgery (SRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H610740485\">",
"     'Stereotactic body radiotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Disease extent also influences outcomes. Complete subarachnoid block produced by the tumor is a poor prognostic sign [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/5,53\">",
"     5,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Dose and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of EBRT schedules have been used, ranging from single large fractions (eg, 8 Gy) to protracted courses (eg, 40 Gy divided in 20 fractions).",
"   </p>",
"   <p>",
"    The impact of dose and schedule of RT is illustrated by several major studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study compared 30 Gy in 10 fractions (114 patients) versus 40 Gy in 20 fractions (117 patients), assigning treatment based upon appointment availability [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/54\">",
"       54",
"      </a>",
"      ]. Although not randomly assigned, the two groups were similar in all parameters. There were no significant differences in functional outcome (posttreatment motor function or the percentage of patients regaining ambulation) or overall survival between the groups. However, long-course EBRT was associated with significantly better local control (77 versus 61 percent) and 12-month progression-free survival (72 versus 55 percent).",
"      <br/>",
"      <br/>",
"      A larger retrospective analysis of 577 patients treated with 37.5 Gy in 15 fractions also failed to demonstrate an advantage compared to 30 Gy in 10 fractions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of over 1300 patients examined five treatment schedules ranging from a single treatment of 8 Gy to a total of 40 Gy in 20 fractions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/56\">",
"       56",
"      </a>",
"      ]. All five regimens gave similar functional results, although the more protracted schedules were associated with fewer recurrences within the radiation treatment volume. Although no benefit was observed for prolonged treatment in most tumor types [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/47,57\">",
"       47,57",
"      </a>",
"      ], patients with multiple myeloma were an exception and had a better functional result with a more protracted course of treatment (30 Gy to 40 Gy in 10 or more fractions) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the only randomized trial addressing this issue directly, 300 patients with an estimated life expectancy of less than six months were randomly assigned to two different hypofractionated EBRT regimens: two fractions of 8 Gy (16 Gy total dose) or split course RT with eight fractions administered as 5 Gy x 3, and 3 Gy x 5 (30 Gy total dose) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/44\">",
"       44",
"      </a>",
"      ]. Both schedules were similarly effective and there were no differences in short-term toxicity, rate of ambulation or in-field recurrence rate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a relatively short life expectancy, a short course of EBRT (eg, one fraction of 8 Gy) affords similar palliation, without the inconvenience of a more protracted treatment course [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/44,54,56,59\">",
"     44,54,56,59",
"    </a>",
"    ]. In a phase III trial in which 327 patients with ESCC and a short life expectancy were randomly assigned to two fractions of 8 Gy (16 Gy total dose) or single dose of 8 Gy, no differences in response or overall survival (median 4 months) were found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24824955\">",
"    <span class=\"h4\">",
"     Prognostic factors and predicting outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostic factors associated with shortened survival after RT include relatively radioresistant histology, the presence of visceral metastases or other bone metastases, nonambulatory status at treatment, an interval from the original diagnosis to ESCC &le;15 months, and an interval &gt;14 days from the onset of motor symptoms to the initiation of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/41,60\">",
"     41,60",
"    </a>",
"    ]. On the other hand, patients with a prolonged natural history, oligometastatic disease without visceral involvement, a slow progression of motor deficits, and myeloma, lymphoma, or breast cancer may derive benefit from a more protracted course of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A scoring system has been developed based upon these factors that permits stratification according to the probability of short-term survival and likelihood of retaining or regaining ambulatory function after RT for metastatic epidural spinal cord compression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/41\">",
"     41",
"    </a>",
"    ]. The points assigned in each prognostic category are depicted in the table (",
"    <a class=\"graphic graphic_table graphicRef73749 \" href=\"UTD.htm?8/54/9069\">",
"     table 2",
"    </a>",
"    ). Within each of the five prognostic stratification levels, the six-month survival rates for patients with &le;28, 29 to 31, 32 to 34, 35 to 37, and &ge;38 total points were 6, 31, 42, 61, and 93 percent, respectively, while the corresponding post-RT ambulatory rates were 6, 44, 70, 86, and 99 percent, respectively. The authors postulated that such a scoring system could be used to select patients with poor functional outcome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    survival for palliative short-course versus conventional fractionation RT.",
"   </p>",
"   <p>",
"    This prognostic scoring system has been validated by the same group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In the validation cohort assessing overall survival following RT, there was a reduction from five prognostic stratification levels to three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      20 to 30 points  14 percent six-month survival",
"     </li>",
"     <li>",
"      31 to 35 points  56 percent six-month survival",
"     </li>",
"     <li>",
"      36 to 45 points  80 percent six-month survival",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent validation of this model is needed.",
"   </p>",
"   <p>",
"    The same issues apply to the management of elderly patients. A retrospective analysis of 308 patients &ge;75 years did not demonstrate any differences in prognosis as compared to younger individuals and indicated that the same criteria should be applied in determining the dose and fractionation schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679513276\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;EBRT is appropriate definitive therapy for patients who are not considered surgical candidates and who have relatively radiosensitive tumors. It is also indicated after surgical decompression. For patients with a relatively short life expectancy, a brief course of EBRT (eg, a single fraction of 8 Gy) affords similar palliation, without the inconvenience of a more protracted treatment course. Patients with a prolonged natural history, oligometastatic disease without visceral involvement, slow progression of motor deficits, and histologic diagnosis of myeloma, lymphoma, or breast cancer may derive benefit from a more protracted course of RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610740485\">",
"    <span class=\"h3\">",
"     Stereotactic body radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of conventional EBRT is limited by the spinal cord, which is intolerant of high dose RT. Stereotactic body radiation therapy (SBRT), also known as stereotactic radiosurgery, is a technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors, even in close proximity to the spinal cord, in either a single or limited number of dose fractions. Although high doses can be delivered, normal tissue constraints are always respected, especially for the spinal cord. This frequently results in tumor adjacent to the spinal cord receiving a lower dose than tumor further away from the spinal cord. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link&amp;anchor=H2#H2\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Rationale'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While conventional EBRT is effective for the treatment of relatively radiosensitive neoplasms (eg, breast, prostate, ovarian cancer, SCLC, myeloma, lymphoma), it is less useful for relatively radioresistant tumors, especially renal cell carcinoma and melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/45\">",
"     45",
"    </a>",
"    ]. There is increasing evidence that SBRT with a single 24 Gy fraction gives excellent pain relief and local tumor control in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    The largest study detailed outcomes from SBRT (12.5 to 25 Gy, median 20 Gy) treatment of 500 spinal metastases in 393 patients (including 93 renal cell, and 38 melanoma metastases); the vast majority (69 percent) had received prior radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients with overt spinal instability, neurological deficits from bony compression of neural structures, or myelopathy or cauda equina syndrome from direct tumor compression were excluded. Long-term pain improvement was experienced by 86 percent of all patients, including 94 percent of those with renal cell cancer and 96 percent of patients with melanoma. Long-term tumor control was achieved in 90 percent of lesions treated with SRS as a primary treatment modality, including 87 percent of patients with renal cell cancer and 75 percent of those with melanoma. Of the 32 patients with a progressive neurologic deficit prior to treatment, 27 (84 percent) improved clinically.",
"   </p>",
"   <p>",
"    While studies such as these illustrate the efficacy of SBRT in the treatment of spine metastases, they excluded patients with ESCC. However, there is increasing evidence that SBRT is a viable noninvasive treatment option for malignant epidural disease in the absence of high-grade spinal cord compression: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single fraction SBRT (median of 16 Gy) was administered to 31 multiple myeloma lesions causing ESCC in 24 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/68\">",
"       68",
"      </a>",
"      ]. Overall pain control was 86 percent. Seven patients presented with neurological deficits and five neurologically improved or normalized after SBRT. Complete radiographic response of the epidural tumor was noted in 81 percent at three months after SBRT. During the follow-up time, there was no radiographic or neurological progression at the treated spine.",
"     </li>",
"     <li>",
"      A second clinical trial of single fraction SBRT (median of 16 Gy) included 62 patients with a total of 85 lesions causing metastatic ESCC. All patients had muscle power 4 of 5 or better. The mean epidural tumor volume reduction was 65 percent at two months after radiosurgery. Thecal sac patency improved from 55 to 76 percent (p&lt;.001). Overall, neurological function improved in 81 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/69\">",
"       69",
"      </a>",
"      ]. Relatively high doses of SBRT must be used to achieve optimal results [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/69\">",
"       69",
"      </a>",
"      ]. Thus effective SBRT can only be performed at these doses in the absence of a high-grade cord compression (ie, spinal cord compression or deformation of the thecal sac with spinal cord abutment but without cord compression). Patients with high-grade cord compression are only appropriate for SBRT if they have undergone surgical decompression first. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link&amp;anchor=H10#H10\">",
"       \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Spinal and paraspinal tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-dose single-fraction SBRT (18 to 24 Gy) has also been applied following surgical decompression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/67\">",
"     67",
"    </a>",
"    ]. In a retrospective series of 21 patients treated with this approach, local tumor control was maintained until death or most recent follow-up in 17 (81 percent), and neurologic function was preserved. Three of the four failures had received low dose SRS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679513262\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiotherapy (SBRT) with a single 24 Gy fraction gives excellent tumor control, even in patients who have relatively radioresistant tumors such as melanoma and renal cell cancer, and an early diagnosis of ESCC before high-grade spinal cord compression has developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no intrinsic reasons why chemotherapy cannot be used to treat ESCC. However, most patients with ESCC have a tumor that is not chemosensitive. In those patients with a chemosensitive malignancy, chemotherapy is an attractive option because it can also treat tumor deposits elsewhere in the body.",
"   </p>",
"   <p>",
"    Tumors in which chemotherapy has been used to successfully treat ESCC include Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/70\">",
"     70",
"    </a>",
"    ], non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/71\">",
"     71",
"    </a>",
"    ], neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/72\">",
"     72",
"    </a>",
"    ], germ cell neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/73\">",
"     73",
"    </a>",
"    ], and breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/74\">",
"     74",
"    </a>",
"    ]. Patients with prostate cancer and breast cancer may also derive benefit from hormonal manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H20#H20\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Epidural spinal cord compression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Novel approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolization of highly vascular neoplasms has occasionally been used as an adjunct to surgery. In one case report, a patient with renal cell carcinoma had two temporally distinct episodes of ESCC at different locations in the spinal cord successfully treated with transarterial embolization utilizing microcoils and alcohol particles [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679515190\">",
"    <span class=\"h2\">",
"     Implications for survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival in large series following the diagnosis of ESCC is approximately six months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/2,3,6,77\">",
"     2,3,6,77",
"    </a>",
"    ]. The outcome is better in ambulatory patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3,6,78\">",
"     3,6,78",
"    </a>",
"    ], and approximately one-half of patients surviving one year are still ambulatory at that time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/7\">",
"     7",
"    </a>",
"    ]. The median survival for patients ambulatory prior to RT is eight to ten months compared to two to four months for those who are nonambulatory [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3,79\">",
"     3,79",
"    </a>",
"    ]. For those who remain nonambulatory at the conclusion of RT, the median survival is only one month [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is also better in patients with breast or prostate cancer and significantly worse with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/2,3,78\">",
"     2,3,78",
"    </a>",
"    ]. Studies suggest a median survival of nine to ten months for breast and prostate cancer, lymphoma, and multiple myeloma compared to three months for lung cancer.",
"   </p>",
"   <p>",
"    Similar observations have been made when survival after spinal metastasis is examined (irrespective of whether the patient has ESCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/38,80,81\">",
"     38,80,81",
"    </a>",
"    ]. Patients with radiosensitive tumors and a single spinal metastasis do best, while patients with lung cancer, multiple vertebral metastases, or visceral or brain metastases fare poorly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679513881\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF RECURRENT ESCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following primary treatment for ESCC, patients are at risk for recurrent ESCC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/8,52,82,83\">",
"     8,52,82,83",
"    </a>",
"    ]. The risk of recurrence can be illustrated by a prospective study that followed 103 patients diagnosed between 1984 and 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/83\">",
"     83",
"    </a>",
"    ]. Recurrent spinal epidural metastases occurred in 20 percent after a median interval of seven months, and 11 percent developed a second recurrence. Recurrent spinal epidural metastases occurred as often at the same initial level (55 percent) as at a remote level (45 percent). About one-half of two-year survivors, and nearly all three-year survivors developed recurrent spinal epidural metastases. However, treatment resulted in preservation of ambulatory status in most patients, even after the second recurrence.",
"   </p>",
"   <p>",
"    The options for retreatment are stereotactic body radiotherapy (SBRT), a second course of conventional spine RT, surgery, or systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/65,84-89\">",
"     65,84-89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of SBRT was shown in a previously described detailed report of 500 spinal metastases in 393 patients, the vast majority (69 percent) of whom were treated with high-dose SBRT for radiographic tumor progression after conventional EBRT [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/65\">",
"       65",
"      </a>",
"      ]. Long-term tumor control was achieved in 88 percent.",
"     </li>",
"     <li>",
"      Retrospective data suggest that a second course of EBRT can be given reasonably safely to patients with no other satisfactory options [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/44,59,85,90\">",
"       44,59,85,90",
"      </a>",
"      ]. The importance of ambulatory status at the time of reirradiation on motor function was shown in an analysis of data from two randomized trials of hypofractionated RT for initial treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/44,59\">",
"       44,59",
"      </a>",
"      ]; 24 patients had an in-field recurrence, of whom 12 underwent reirradiation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/90\">",
"       90",
"      </a>",
"      ]. None of the five non-ambulatory patients regained the ability to walk, while six of seven ambulatory patients retained ambulation. The median survival after reirradiation was five months, and the median duration of response was 4.5 months.",
"      <br/>",
"      <br/>",
"      Although reirradiation may result in a cumulative dose exceeding the reported radiation tolerance of the spinal cord (45 Gy in 2 Gy fractions), radiation myelopathy in this setting is an infrequent occurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]. This may be attributable to repair of sublethal radiation damage between courses [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/91\">",
"       91",
"      </a>",
"      ]",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the generally short survival of patients receiving repeat irradiation (median, five months) compared to the latency of radiation myelopathy. In addition, some radiation oncologists have argued that spinal cord tolerance has been defined too conservatively and probably is closer to 60 Gy in 2 Gy fractions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/92\">",
"       92",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A new approach to reirradiation using helical tomography can achieve high rates of local control and pain relief without spinal cord damage as long as the spinal cord is not directly compressed [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In carefully selected cases, a second decompressive surgery could be considered. In a series of 39 patients who underwent reoperation because of tumor recurrence causing high-grade ESCC, 65 percent remained ambulatory until death or last follow-up, and functional status was maintained or improved in 97 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/21/26970/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11522?source=see_link\">",
"       \"Patient information: Cauda equina syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplastic epidural spinal cord compression (ESCC) is a common complication of cancer that can cause pain and potentially irreversible loss of neurologic function. We consider any radiologic evidence of indentation of the thecal sac to be evidence for ESCC. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The majority of cases arise from epidural extension of vertebral body metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prompt diagnosis and immediate treatment are critically important in the preservation of neurological function in patients with epidural spinal cord compression (ESCC). (See",
"    <a class=\"local\" href=\"#H679514895\">",
"     'Impact of treatment delay on posttreatment ambulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The goals of treatment for patients with ESCC are pain control, avoidance of complications from local disease progression, and the preservation or improvement of neurologic functioning. The choice of definitive treatment must be appropriate to the patient's burden of disease, life expectancy, and values. An important component of the pretreatment decision making process is an assessment of spinal instability. (See",
"    <a class=\"local\" href=\"#H679515503\">",
"     'Assessing spinal stability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with ESCC and either neurologic symptoms or substantial thecal sac compression by imaging, we recommend glucocorticoids as an integral component of the initial management (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Glucocorticoids'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe neurologic deficits (eg, paraparesis or paraplegia), we suggest high-dose glucocorticoid therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      96 mg intravenously followed by 24 mg four times daily for three days and then tapered over 10 days) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with minimal neurologic symptoms, we suggest moderate doses of glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      as a bolus of 10 mg intravenously followed by 16 mg daily orally in divided doses) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that glucocorticoids be omitted in patients with small epidural lesions and a normal neurologic examination (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Definitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery, external beam RT, and stereotactic body radiotherapy (SBRT) are the primary approaches to treat tumor compressing the spinal cord. We suggest an algorithmic approach to the selection of definitive treatment (",
"    <a class=\"graphic graphic_table graphicRef80396 \" href=\"UTD.htm?14/24/14733\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with metastatic ESCC and an unstable spine who have a limited disease burden and relatively favorable prognosis, we suggest decompressive resection and stabilization followed by radiation therapy rather than EBRT alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radical resection followed by RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Following surgery, we suggest a relatively longer course of RT (eg, 30 Gy in 10 fractions) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We do not use shorter courses of radiation in this setting. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with an unstable spine who are not candidates for radical surgery may derive some symptomatic benefit from minimally invasive techniques such as vertebroplasty and kyphoplasty, followed by EBRT.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H679516192\">",
"       'Vertebroplasty and kyphoplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with extensive systemic disease and poor performance status with expected survival of only a few months, we suggest RT alone for symptom palliation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest a short course of radiation (eg, one treatment of 8 Gy) instead of a more protracted treatment schedule (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'External beam RT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with metastatic ESCC and a stable spine, we suggest EBRT alone rather than surgery for patients with radiosensitive neoplasms (eg, breast cancer, lymphoma, myeloma) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'External beam RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In most cases, we suggest a relatively long course of RT (eg, 30 Gy in 10 fractions) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dose and schedule'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a stable spine who have relatively radioresistant neoplasms (eg, renal cell cancer, melanoma) and no evidence of high-grade cord compression, we suggest SBRT rather than EBRT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If there is evidence of high-grade cord compression, SBRT should not be undertaken, and surgical decompression followed by radiation therapy or by stereotactic radiosurgery is an appropriate option as long as the patient is well enough to tolerate the procedure, has a limited disease burden, and relatively favorable prognosis. (See",
"      <a class=\"local\" href=\"#H610740485\">",
"       'Stereotactic body radiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemotherapy and hormonal therapy may be useful in the treatment of ESCC in patients with sensitive tumors (eg, hematologic malignancies, germ cell tumors, breast cancer, prostate cancer). The advantages of surgery over RT to decompress the spinal cord are uncertain in these patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimally invasive techniques like vertebroplasty and kyphoplasty are only appropriate for patients with symptomatic spinal metastases without epidural disease or retropulsion of bone fragments into the spinal cord. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=see_link&amp;anchor=H380436962#H380436962\">",
"       \"Cancer pain management: Interventional therapies\", section on 'Vertebroplasty and kyphoplasty'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H679516162\">",
"    <span class=\"h2\">",
"     Recurrent ESCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The options for retreatment are stereotactic body radiotherapy (SBRT), a second course of conventional spine RT, surgery, or systemic therapy. The treatment choice must be individualized. (See",
"    <a class=\"local\" href=\"#H679513881\">",
"     'Management of recurrent ESCC'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/1\">",
"      Loblaw DA, Perry J, Chambers A, Laperriere NJ. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005; 23:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/2\">",
"      Schiff D, O'Neill BP, Wang CH, O'Fallon JR. Neuroimaging and treatment implications of patients with multiple epidural spinal metastases. Cancer 1998; 83:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/3\">",
"      Maranzano E, Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. Int J Radiat Oncol Biol Phys 1995; 32:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/4\">",
"      Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) 1990; 107:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/5\">",
"      Helweg-Larsen S, Johnsen A, Boesen J, S&oslash;rensen PS. Radiologic features compared to clinical findings in a prospective study of 153 patients with metastatic spinal cord compression treated by radiotherapy. Acta Neurochir (Wien) 1997; 139:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/6\">",
"      Maranzano E, Latini P, Beneventi S, et al. Comparison of two different radiotherapy schedules for spinal cord compression in prostate cancer. Tumori 1998; 84:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/7\">",
"      Kim RY, Spencer SA, Meredith RF, et al. Extradural spinal cord compression: analysis of factors determining functional prognosis--prospective study. Radiology 1990; 176:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/8\">",
"      Greenberg HS, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol 1980; 8:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/9\">",
"      Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy of spinal cord compression caused by breast cancer: report of a prospective trial. Int J Radiat Oncol Biol Phys 1992; 24:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/10\">",
"      Maranzano E, Latini P, Checcaglini F, et al. Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients. Cancer 1991; 67:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/11\">",
"      Martenson JA Jr, Evans RG, Lie MR, et al. Treatment outcome and complications in patients treated for malignant epidural spinal cord compression (SCC). J Neurooncol 1985; 3:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/12\">",
"      Findlay GF. Adverse effects of the management of malignant spinal cord compression. J Neurol Neurosurg Psychiatry 1984; 47:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/13\">",
"      Husband DJ. Malignant spinal cord compression: prospective study of delays in referral and treatment. BMJ 1998; 317:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/14\">",
"      Rades D, Huttenlocher S, Dunst J, et al. Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol 2010; 28:3597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/15\">",
"      Fadul CE, Lemann W, Thaler HT, Posner JB. Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease. Neurology 1988; 38:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/16\">",
"      George R, Jeba J, Ramkumar G, et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 2008; :CD006716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/17\">",
"      Loblaw DA, Mitera G, Ford M, Laperriere NJ. A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. Int J Radiat Oncol Biol Phys 2012; 84:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/18\">",
"      Ushio Y, Posner R, Kim JH, et al. Treatment of experimental spinal cord compression caused by extradural neoplasms. J Neurosurg 1977; 47:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/19\">",
"      Delattre JY, Arbit E, Rosenblum MK, et al. High dose versus low dose dexamethasone in experimental epidural spinal cord compression. Neurosurgery 1988; 22:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/20\">",
"      S&oslash;rensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994; 30A:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/21\">",
"      Vecht CJ, Haaxma-Reiche H, van Putten WL, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989; 39:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/22\">",
"      Graham PH, Capp A, Delaney G, et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. Clin Oncol (R Coll Radiol) 2006; 18:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/23\">",
"      Heimdal K, Hirschberg H, Sletteb&oslash; H, et al. High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol 1992; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/24\">",
"      Maranzano E, Latini P, Beneventi S, et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. Am J Clin Oncol 1996; 19:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/25\">",
"      Lee SH, Cox KM, Grant R, et al. Patient positioning (mobilisation) and bracing for pain relief and spinal stability in metastatic spinal cord compression in adults. Cochrane Database Syst Rev 2012; 3:CD007609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/26\">",
"      Wang JC, Boland P, Mitra N, et al. Single-stage posterolateral transpedicular approach for resection of epidural metastatic spine tumors involving the vertebral body with circumferential reconstruction: results in 140 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 2004; 1:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/27\">",
"      Mendel E, Bourekas E, Gerszten P, Golan JD. Percutaneous techniques in the treatment of spine tumors: what are the diagnostic and therapeutic indications and outcomes? Spine (Phila Pa 1976) 2009; 34:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/28\">",
"      Mut M, Schiff D, Shaffrey ME. Metastasis to nervous system: spinal epidural and intramedullary metastases. J Neurooncol 2005; 75:43.",
"     </a>",
"    </li>",
"    <li>",
"     Fehlings MD, Furlan J, Bilsky M, et al. Defining spinal instability of the cervical spine: Can the available evidence guide clinical practice? Spine [in press].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/30\">",
"      Weber MH, Burch S, Buckley J, et al. Instability and impending instability of the thoracolumbar spine in patients with spinal metastases: a systematic review. Int J Oncol 2011; 38:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/31\">",
"      Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976) 2010; 35:E1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/32\">",
"      Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 2011; 29:3072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/33\">",
"      Young RF, Post EM, King GA. Treatment of spinal epidural metastases. Randomized prospective comparison of laminectomy and radiotherapy. J Neurosurg 1980; 53:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/34\">",
"      Siegal T, Siegal T, Robin G, et al. Anterior decompression of the spine for metastatic epidural cord compression: a promising avenue of therapy? Ann Neurol 1982; 11:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/35\">",
"      Harrington KD. Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy. Clin Orthop Relat Res 1988; :177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/36\">",
"      Sundaresan N, Sachdev VP, Holland JF, et al. Surgical treatment of spinal cord compression from epidural metastasis. J Clin Oncol 1995; 13:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/37\">",
"      Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/38\">",
"      Sioutos PJ, Arbit E, Meshulam CF, Galicich JH. Spinal metastases from solid tumors. Analysis of factors affecting survival. Cancer 1995; 76:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/39\">",
"      Prasad D, Schiff D. Malignant spinal-cord compression. Lancet Oncol 2005; 6:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/40\">",
"      Chi JH, Gokaslan Z, McCormick P, et al. Selecting treatment for patients with malignant epidural spinal cord compression-does age matter?: results from a randomized clinical trial. Spine (Phila Pa 1976) 2009; 34:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/41\">",
"      Rades D, Rudat V, Veninga T, et al. A score predicting posttreatment ambulatory status in patients irradiated for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2008; 72:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/42\">",
"      van den Bent MJ. Surgical resection improves outcome in metastatic epidural spinal cord compression. Lancet 2005; 366:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/43\">",
"      Klish DS, Grossman P, Allen PK, et al. Irradiation of spinal metastases: should we continue to include one uninvolved vertebral body above and below in the radiation field? Int J Radiat Oncol Biol Phys 2011; 81:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/44\">",
"      Maranzano E, Bellavita R, Rossi R, et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 2005; 23:3358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/45\">",
"      Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine (Phila Pa 1976) 2009; 34:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/46\">",
"      Zelefsky MJ, Scher HI, Krol G, et al. Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy. Cancer 1992; 70:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/47\">",
"      Rades D, Walz J, Stalpers LJ, et al. Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: results of a retrospective multi-center study. Eur Urol 2006; 49:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/48\">",
"      Rades D, Heidenreich F, Karstens JH. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2002; 53:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/49\">",
"      Zaidat OO, Ruff RL. Treatment of spinal epidural metastasis improves patient survival and functional state. Neurology 2002; 58:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/50\">",
"      Helweg-Larsen S, Rasmusson B, S&oslash;rensen PS. Recovery of gait after radiotherapy in paralytic patients with metastatic epidural spinal cord compression. Neurology 1990; 40:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/51\">",
"      Katagiri H, Takahashi M, Inagaki J, et al. Clinical results of nonsurgical treatment for spinal metastases. Int J Radiat Oncol Biol Phys 1998; 42:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/52\">",
"      Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978; 3:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/53\">",
"      Tomita T, Galicich JH, Sundaresan N. Radiation therapy for spinal epidural metastases with complete block. Acta Radiol Oncol 1983; 22:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/54\">",
"      Rades D, Lange M, Veninga T, et al. Preliminary results of spinal cord compression recurrence evaluation (score-1) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression. Int J Radiat Oncol Biol Phys 2009; 73:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/55\">",
"      Rades D, Karstens JH, Hoskin PJ, et al. Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2007; 67:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/56\">",
"      Rades D, Stalpers LJ, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 2005; 23:3366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/57\">",
"      Rades D, Stalpers LJ, Schulte R, et al. Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. Eur J Cancer 2006; 42:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/58\">",
"      Rades D, Hoskin PJ, Stalpers LJ, et al. Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 2006; 64:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/59\">",
"      Maranzano E, Trippa F, Casale M, et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol 2009; 93:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/60\">",
"      Rades D, Fehlauer F, Schulte R, et al. Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 2006; 24:3388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/61\">",
"      Rades D, Veninga T, Stalpers LJ, et al. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol 2007; 25:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/62\">",
"      Rades D, Douglas S, Veninga T, et al. Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer 2010; 116:3670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/63\">",
"      Rades D, Douglas S, Huttenlocher S, et al. Validation of a score predicting post-treatment ambulatory status after radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 2011; 79:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/64\">",
"      Rades D, Hoskin PJ, Karstens JH, et al. Radiotherapy of metastatic spinal cord compression in very elderly patients. Int J Radiat Oncol Biol Phys 2007; 67:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/65\">",
"      Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 2007; 32:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/66\">",
"      Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 2008; 71:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/67\">",
"      Moulding HD, Elder JB, Lis E, et al. Local disease control after decompressive surgery and adjuvant high-dose single-fraction radiosurgery for spine metastases. J Neurosurg Spine 2010; 13:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/68\">",
"      Jin R, Rock J, Jin JY, et al. Single fraction spine radiosurgery for myeloma epidural spinal cord compression. J Exp Ther Oncol 2009; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/69\">",
"      Ryu S, Rock J, Jain R, et al. Radiosurgical decompression of metastatic epidural compression. Cancer 2010; 116:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/70\">",
"      Burch PA, Grossman SA. Treatment of epidural cord compressions from Hodgkin's disease with chemotherapy. A report of two cases and a review of the literature. Am J Med 1988; 84:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/71\">",
"      Wong ET, Portlock CS, O'Brien JP, DeAngelis LM. Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma. Neurology 1996; 46:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/72\">",
"      Hayes FA, Thompson EI, Hvizdala E, et al. Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. J Pediatr 1984; 104:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/73\">",
"      Grommes C, Bosl GJ, DeAngelis LM. Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. Cancer 2011; 117:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/74\">",
"      Boogerd W, van der Sande JJ, Kr&ouml;ger R, et al. Effective systemic therapy for spinal epidural metastases from breast carcinoma. Eur J Cancer Clin Oncol 1989; 25:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/75\">",
"      Sasagawa I, Gotoh H, Miyabayashi H, et al. Hormonal treatment of symptomatic spinal cord compression in advanced prostatic cancer. Int Urol Nephrol 1991; 23:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/76\">",
"      Kuether TA, Nesbit GM, Barnwell SL. Embolization as treatment for spinal cord compression from renal cell carcinoma: case report. Neurosurgery 1996; 39:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/77\">",
"      S&oslash;rensen S, B&oslash;rgesen SE, Rohde K, et al. Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer 1990; 65:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/78\">",
"      Rades D, Veninga T, Stalpers LJ, et al. Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. Int J Radiat Oncol Biol Phys 2006; 64:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/79\">",
"      Huang J, Jatoi A. Morbidity and mortality in patients with cancer who become nonambulatory after spinal cord compression: a case series on end-of-life care. J Palliat Med 2009; 12:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/80\">",
"      Tatsui H, Onomura T, Morishita S, et al. Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. Spine (Phila Pa 1976) 1996; 21:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/81\">",
"      Bauer HC, Wedin R. Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients. Acta Orthop Scand 1995; 66:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/82\">",
"      Loeffler JS, Glicksman AS, Tefft M, Gelch M. Treatment of spinal cord compression: a retrospective analysis. Med Pediatr Oncol 1983; 11:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/83\">",
"      van der Sande JJ, Boogerd W, Kr&ouml;ger R, Kappelle AC. Recurrent spinal epidural metastases: a prospective study with a complete follow up. J Neurol Neurosurg Psychiatry 1999; 66:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/84\">",
"      Schiff D, Shaw EG, Cascino TL. Outcome after spinal reirradiation for malignant epidural spinal cord compression. Ann Neurol 1995; 37:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/85\">",
"      Rades D, Rudat V, Veninga T, et al. Prognostic factors for functional outcome and survival after reirradiation for in-field recurrences of metastatic spinal cord compression. Cancer 2008; 113:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/86\">",
"      Wright JL, Lovelock DM, Bilsky MH, et al. Clinical outcomes after reirradiation of paraspinal tumors. Am J Clin Oncol 2006; 29:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/87\">",
"      Nieder C, Grosu AL, Andratschke NH, Molls M. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Radiat Oncol Biol Phys 2005; 61:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/88\">",
"      Milker-Zabel S, Zabel A, Thilmann C, et al. Clinical results of retreatment of vertebral bone metastases by stereotactic conformal radiotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/89\">",
"      Garg AK, Wang XS, Shiu AS, et al. Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience. Cancer 2011; 117:3509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/90\">",
"      Maranzano E, Trippa F, Casale M, et al. Reirradiation of metastatic spinal cord compression: definitive results of two randomized trials. Radiother Oncol 2011; 98:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/91\">",
"      Ang KK, Price RE, Stephens LC, et al. The tolerance of primate spinal cord to re-irradiation. Int J Radiat Oncol Biol Phys 1993; 25:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/92\">",
"      Schultheiss TE, Stephens LC. Invited review: permanent radiation myelopathy. Br J Radiol 1992; 65:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/93\">",
"      Sterzing F, Hauswald H, Uhl M, et al. Spinal cord sparing reirradiation with helical tomotherapy. Cancer 2010; 116:3961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/21/26970/abstract/94\">",
"      Laufer I, Hanover A, Lis E, et al. Repeat decompression surgery for recurrent spinal metastases. J Neurosurg Spine 2010; 13:109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2820 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26970=[""].join("\n");
var outline_f26_21_26970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H679514895\">",
"      Impact of treatment delay on posttreatment ambulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      General principles of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H679512095\">",
"      Definitive treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H679515503\">",
"      - Assessing spinal stability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radical resection followed by RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H679516192\">",
"      Vertebroplasty and kyphoplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - External beam RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H679512734\">",
"      Response to treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dose and schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H24824955\">",
"      Prognostic factors and predicting outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H679513276\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H610740485\">",
"      - Stereotactic body radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H679513262\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Novel approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H679515190\">",
"      Implications for survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H679513881\">",
"      MANAGEMENT OF RECURRENT ESCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Definitive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H679516162\">",
"      Recurrent ESCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2820|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/17/35102\" title=\"algorithm 1\">",
"      ESCC mgnt algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/24/14733\" title=\"table 1\">",
"      Spine instability score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/54/9069\" title=\"table 2\">",
"      Post RT ambul rates scores",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11522?source=related_link\">",
"      Patient information: Cauda equina syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_21_26971="Pyrazinamide dosing";
var content_f26_21_26971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested pyrazinamide doses, using whole tablets, for adults weighing 40-90 kilograms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Weight (kg)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        40-55",
"       </td>",
"       <td class=\"subtitle2\">",
"        56-75",
"       </td>",
"       <td class=\"subtitle2\">",
"        76-90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daily, mg (mg/kg)",
"       </td>",
"       <td>",
"        1000 (18.2-25.0)",
"       </td>",
"       <td>",
"        1500 (20.0-26.8)",
"       </td>",
"       <td>",
"        2000&bull; (22.2-26.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrice weekly, mg (mg/kg)",
"       </td>",
"       <td>",
"        1500 (27.3-37.5)",
"       </td>",
"       <td>",
"        2500 (33.3-44.6)",
"       </td>",
"       <td>",
"        3000&bull; (33.3-39.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Twice weekly, mg (mg/kg)",
"       </td>",
"       <td>",
"        2000 (36.4-50.0)",
"       </td>",
"       <td>",
"        3000 (40.0-53.6)",
"       </td>",
"       <td>",
"        4000&bull; (44.4-52.6)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on estimated lean body weight.",
"     <br>",
"      &bull; Maximum dose regardless of weight.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Blumberg, HM, Burman, WJ, Chaisson, RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603. Official Journal of the American Thoracic Society. Copyright &copy;2003 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26971=[""].join("\n");
var outline_f26_21_26971=null;
var title_f26_21_26972="Cardiac injury scale";
var content_f26_21_26972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cardiac injury scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury description",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        I",
"       </td>",
"       <td>",
"        Blunt cardiac injury with minor ECG abnormality (nonspecific ST or T wave changes, premature atrial or ventricular contraction, or persistent sinus tachycardia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt or penetrating pericardial wound without cardiac injury, cardiac tamponade, or cardiac herniation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        II",
"       </td>",
"       <td>",
"        Blunt cardiac injury with heart block or ischemic changes without cardiac failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penetrating tangential cardiac wound up to but not extending through endocardium, without tamponade",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        III",
"       </td>",
"       <td>",
"        Blunt cardiac injury with sustained or multifocal ventricular contractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt or penetrating cardiac injury with septal rupture, pulmonary or tricuspid incompetence, papillary muscle dysfunction, or distal coronary artery occlusion without cardiac failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt pericardial laceration with cardiac herniation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt cardiac injury with cardiac failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penetrating tangential myocardial wound up to but not through endocardium, with tamponade",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        IV",
"       </td>",
"       <td>",
"        Blunt or penetrating cardiac injury with septal rupture, pulmonary or tricuspid incompetence, papillary muscle dysfunction, or distal coronary artery occlusion producing cardiac failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt or penetrating cardiac injury with aortic or mitral incompetence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt or penetrating cardiac injury of the right ventricle, right or left atrium",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        V",
"       </td>",
"       <td>",
"        Blunt or penetrating cardiac injury with proximal coronary artery occlusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt or penetrating left ventricular perforation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stellate injuries &lt;50 percent tissue loss of the right ventricle, right or left atrium",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        VI",
"       </td>",
"       <td>",
"        Blunt avulsion of the heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penetrating wound producing &gt;50 percent tissue loss of a chamber",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Advance one grade for multiple penetrating wounds to a single chamber or multiple chamber involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore EE, Malangoni MA, Cogbill TH, et al. Organ injury scaling. IV: Thoracic vascular, lung, and diaphragm. J Trauma 1994; 36:299. Copyright &copy; 1994 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26972=[""].join("\n");
var outline_f26_21_26972=null;
var title_f26_21_26973="Hepatocellular Ca hep C";
var content_f26_21_26973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Hepatocellular carcinoma in cirrhosis due to hepatitis C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A study of 384 patients with compensated cirrhosis due to hepatitis C virus infection found that 1.4 percent of patients per year developed hepatocellular carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fattovich, G, Giustina, G, Degos, F, et al, Gastroenterology 1997; 112:463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26973=[""].join("\n");
var outline_f26_21_26973=null;
var title_f26_21_26974="Hemorrhage during extraction";
var content_f26_21_26974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Potential complications of foreign body extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemorrhage complicating the extraction of a foreign body encased in bulky and friable inflammatory tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26974=[""].join("\n");
var outline_f26_21_26974=null;
var title_f26_21_26975="Cystic hygroma CT III";
var content_f26_21_26975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in left axillary region",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan displays a large cyst in the left axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_21_26975=[""].join("\n");
var outline_f26_21_26975=null;
